



Quality and Efficiency: the foundation for success.

Cibides lipogel[®]

Ferachel forte[®]

Flavofort 1500[®]

Medronys epato[®]

Medronys colesterolo[®]

Proliset complex[®]

Proliset duo[®]

Proliset prost[®]

Proliset sport[®]

Proliset vir[®]

Condroxol orto[®]

Condroxol nerv[®]

Condroxol artro[®]

Condroxol osteo[®]

Lattoglobina[®]

Lattoglobina complex[®]

Triacid ovules[®]


NAPREBEN[®] 10% gel

AQMA ITALIA

Quality and Efficiency: the foundation for success.

AQMA Italia is a pharmaceutical company developing high quality and innovative patented products entirely Made in Italy, with the help of its internal Research and Development department. Clinical trials performed on products confirm their efficacy and safety.

The key points of our work are:



**We identify
Your Needs**



We research it!
(synergistic effect for
active substances)



**Maximum concentration
of active ingredients**



Made in Italy



Study Dosage

*Somewhere, Something Incredible Is
Waiting To Be Known*

(Carl Sagan)



AQMA ITALIA, founded in 2017, is a pharmaceutical company that develops high quality products entirely Made in Italy. Its aim is to play an active role in the improvement of the Italian nutraceutical market.

Therefore it invested in building up an internal Research and Development department, obtaining a new line of high standard dietary supplements.

With the experience of distinguished Pharma experts, Aqma creates innovative products according to the highest quality and efficiency standard with the aim of promoting a new care and well-being philosophy, satisfactory and natural at the same time.

Study and composition of active ingredients, use of international patents, production in GMP certified firms and above all collaboration with main players (Public and private Hospitals, Universities, Clinics) are the essential topics of Aqma together with performing clinical trials on products.

WE RESEARCH SYNERGIC ACTIVE SUBSTANCES

In AQMA Study-Center deep analysis through specialized laboratories are carried out with focus on consumers, specialists, and experts in the pharmaceutical and cosmetic fields.

After hundreds of clinical studies AQMA selected the active substances to be used for creating Aqma products, all MADE IN ITALY, according to the strictest national and international regulations, with proper concentration of the active substances granting high scientific profile and the best results.

PRODUCTS

Our food supplements and medical devices are functional nutraceuticals with therapeutic effects. They are the result of careful researches and development processes with the aim of offering to doctors and customers products useful to improve health, treat chronic diseases, postpone the aging process (and in turn increase life expectancy), or just support functions and integrity of the body. They might be considered healthy sources for facing life threatening diseases such as diabetes, renal and gastrointestinal disorders, as well as different infections and inflammations.

Our team has studied and developed several products that can be used in different medical fields: **General Medicine** (all products), **Cardiovascular Health** (FERACHEL, FLAVOFORT, PROLISET COMPLEX), **Metabolic Disease** (MEDRONYS EPATO, MEDRONYS COLESTEROLO, MEDRONYS GLUCO), **Dermatology** (LATTOGLOBINA, PROLISET COMPLEX), **Neurology** (CONDROXOL NERV, CIBIDES), **Urology** (PROLISET PROST, PROLISET VIR, PROLISET FERT), **Dentistry** (PROLISET COMPLEX, PROLISET DUO), **Otology** (PROLISET COMPLEX, PROLISET DUO, FLAVOFORT), **Osteoarticular system** (CONDROXOL ORTO, CONDROXOL ARTRO, CONDROXOL NERV, CONDROXOL OSTEO, PROLISET DUO, FERACHEL, NAPREBEN, CIBIDES), **Gynaecology** (FERACHEL, LATTOGLOBINA, LATTOGLOBINA COMPLEX, TRIACID OVULES, PROLISET DUO, PROLISET FERT), **Nephrology** (FERACHEL, PROLISET DUO), **Surgery** (PROLISET COMPLEX, PROLISET DUO, FERACHEL) and **Sport Medicine** (PROLISET SPORT).

QUALITY AND EFFICIENCY - RESEARCH AND DEVELOPMENT - VALUE

Aqma products are functional supplements based on **vitamins**, **minerals** and **plant extracts**. Accurate combination of various elements contributes to the physiological functionality in cases of deficiency or increased need for these nutrients. In this catalogue each product is described in full showing all relevant information like ingredients, formulations, packaging and use together with a special section called bibliography dedicated to **clinical studies**. Some more studies carried out so far to confirm the efficacy and safety of final products can be asked sending a mail to our Company. AQMA ITALIA combines consumer needs and research results, therefore Aqma offers a growing number of clinical studies performed on its products.

Aqma **internal medical** information is ready to answer to technical questions in relation to the use, dosage or other requests related to all products. Consumers may also request **further studies** in case of special needs.

Aqma values are **quality, information and controls** with the awareness that all production and distribution chain is performed under international rules and is certified **ISO 9001: 20015** and **GMP**. The utmost attention is paid to compliance with **highest pharmaceutical standards** either in production and in logistics, to certified checks on production, not only as prescribed by current regulations, but with Aqma additional requirements allowing the assessment of the product characteristics. Furthermore Aqma directly **audits** production plants on a constant basis.

Aqma trademarks are unique, registered as word and/or figurative marks at EU level, c/o European Union Intellectual Property Office (EUIPO), granting protection in all nations of European Union.

Aqma is also ready to support its distributors with **marketing, scientific-technical studies**, further information and brochure, as well as **individual training** with our specialists. Marketing support is offered free and can be either in the form already in place, as well as tailor made for specific requirements or countries.

Aqma offers high standard products, and in addition offers knowledge and expertise with support, either direct or through web, without extra costs for its partners.

NEW PRODUCTS



Cibides lipogel®

Effective innovation in the treatment of joints pain.

CLASSIFICATION:

CIBIDES gel contains 3% hemp oil in CBD, escin, Boswellia extract, skinasensyl, bromelain, methylsulfonylmethane, glucosamine sulfate, methyl salicylate.

CHARACTERISTICS

CIBIDES gel is formulated with the aim of providing the patient with an extremely effective product obtained thanks to the combination of several high concentration active ingredients (with documented scientific evidence) in synergy with each other. This makes possible to obtain a highly active gel is easy to use and quick action. Unique and innovative formula enriched by the presence of CBS active hemp extract combined with active ingredients for pain-relieving and anti-inflammatory action.

INDICATIONS

Treatment of localized pains particularly in the orthopedic / rheumatological and traumatological field. In particular it is indicated for the local treatment of painful and inflammatory states that affect:

- articulations, eg osteoarthritis and arthritis
- muscles, eg contractures or injuries
- tendons and ligaments, eg tendinitis

Particularly suitable for the treatment of pain associated with:

dislocations of the shoulder, tendinitis localized to the lower and upper limbs, sprains of the knee and ankle, nocturnal joint pains, muscular pains, muscular contractures, tears and distractions, muscle strains, myalgia, pains in the legs, back pain, stroke of the witch, lower back pain, low back pain.

HOW TO USE

Apply the gel on the painful part and massage gently. Wait for complete absorption of the gel. Repeat the application 2 to 4 times a day.

Available Pack:

gel for topic use 75 ml.



Evidence-based literature:

CANNABIDIOL (CBD):

- 30% reduction of peripheral neuropathic pain (PNP);¹
- 36% reduction of morning pain on movement, caused by rheumatoid arthritis;²
- 45% reduction of morning pain at rest symptoms, caused by rheumatoid arthritis;²

ESCIN:

- +90% global efficacy assessments by investigators in acute impact injuries;³
- +35% of patients with complete resolution of pain from acute impact injuries in 24 hours;³

BOSWELLIA:

- 56% reduction of osteoarticular pain;⁴
- +36% improvement of bone health (reduction of pain and degree of disability);⁴
- 28% reduction of lower back and knee pain;⁴

BROMELAIN VS NSAIDS:

-25% pain reduction;⁵

patients with contusions and hematomas: reduction of signs of ecchymosis in less than 4 days in 78% of treated patients;⁵

METHYLSULFONYLMETHANE:^{6,7}

-35% reduction of joint stiffness;

-58% reduction of pain symptoms;

GLUCOSAMINE AND METHYLSULFONYLMETHANE:

-73% reduction of osteoarticular symptomatology;^{8,9}

+25% improvement of bone function;

double efficacy in reducing osteoarthritis symptoms;

METHYL SALICYLATE:

+40% greater pain relief in patients with muscle strain;¹⁰

+28% of patients with greater scores for pain intensity difference in 8 hours.¹⁰

Bibliography

1. Serpell M, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. *Eur J Pain*. 2014 Aug;18(7):999-1012.
2. Blake DR, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology (Oxford)*. 2006 Jan;45(1):50-2.
3. Wetzel D, et al. Escin/diethylammonium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study. *Br J Sports Med* 2002;36:183-188.
4. Belcaro G, et al. Management of osteoarthritis (OA) with the pharma-standard supplement FlexiQule (Boswellia): a 12-week registry. *Minerva Gastroenterol Dietol*. 2015 Oct 2.
5. Brien S, et al. Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies. *Evid Based Complement Alternat Med*. 2004 Dec; 1(3): 251-257.
6. Kim LS, et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. *Osteoarthritis Cartilage*. 2006 Mar;14(3):286-94.
7. Debbi EM, et al. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study. *BMC Complement Altern Med*. 2011 Jun 27;11:50.
8. Drovanti A, et al. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo-controlled, double blind investigation. *Clinical Therapeutics*, 1980; 3 (4): 260-272.
9. Usha P.R., Naidu MUR. Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis. *Clinical Drug Investigation* 24 (6): 353-363, 2004.
10. Higashi Y, et al. Efficacy and Safety Profile of a Topical Methyl Salicylate and Menthol Patch in Adult Patients With Mild to Moderate Muscle Strain: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study. *Clin Ther*. 2010 Jan;32(1):34-43.

DIETARY SUPPLEMENTS



Ferachel forte®

The evolution of Iron without patient discomfort and with efficacy,
in a shorter time, versus standard therapy.

CLASSIFICATION:

Food supplement based on NaFe3+EDTA® (Ferric sodium EDTA Ferrazone®) Folic acid, Vitamin C, Copper, Selenium and Zinc.

NUTRITION FACTS TABLETS

Average contents	Daily dose (1 tablet)	% NRV*
Ferric Sodium EDTA Iron	230 mg 30 mg	214.3
Vitamin C	150 mg	187.5
Folic Acid	400 mcg	200
Copper	1.8 mg	180
Zinc	12,5 mg	125
Selenomethionine	83 mcg	150.9

*NRV= Daily Reference Nutrition Value (Adult)
(Reg. EU n.1169/2011)

NUTRITION FACTS DROPS

Average contents	Daily dose (children) (1ml)	% VNR*	Daily dose (adults) (2 ml)	% NRV*
Iron	115 mg 15 mg	107	230 mg 30 mg	214
Vitamin C	75 mg	93,75	150 mg	187,5
Zinc	6,25 mg	62,5	12,5 mg	125
Selenium	41,5 mcg	75,45	83 mcg	150,9
Copper	0,9 mg	90	1,8 mg	180
Folic Acid	200 mcg	100	400 mcg	200

*VNR= Daily Reference Nutrition Value (Adult)
(Reg. EU n.1169/2011)

CHARACTERISTICS

Ferachel Forte was formulated with the aim of maximizing iron absorption through an innovative source of iron (Ferric sodium EDTA) in synergy with other nutrients and essential trace elements for the management of anemia. Documented efficacy, with no hassles for the patient, and in shorter times compared to standard therapies:

- very high bioavailability
- efficacy documented in just 24 days of treatment
- high compliance:
 - absence of disorders associated with therapy
 - no cardiovascular risk
 - no pharmacological interaction and/or with food.

Ferric sodium EDTA:

- Patented (Ferrazone®)
- Present in the WHO's guidelines
- Endorsed by EFSA e JECFA

Combined with:

Folic Acid, = rapidity without discomforts
Copper,
Vitamin C
Selenium and Zinc

INDICATIONS

Iron supplement to treat iron deficiency anemia.

- Anemia due to blood loss;
- Reduced iron absorption;
- Anemia from increased need.

Also indicated in inflammatory anemias, such as:

- Anemia due to renal failure;
- Anemia due to chronic intestinal diseases;
- Oncological anemias or other related.

HOW TO USE

Tablets: or adults and children over 10 years of age: 1 to 2 tablets a day, either on an empty stomach or after meals.

Drops: - Children aged 3 years and adolescents: 1 ml per day as it is or dissolved in a glass of water or other suitable liquid (about 150 ml).


- Adults: 2 ml per day as it is or dissolved in a glass of water or other suitable liquid (about 150 ml).
Particularly indicated in the elderly and patients with difficulty swallowing (Dysphagia).

1 tablet = 20 drops.

Ferachel forte®



Ferachel Forte 24 tablets



Ferachel Drops 50 ml

The treatment must be continued for at least 24-72 days (2/2.5 months), so that the iron deposits are completely reconstituted. Treatment can also be performed for longer periods (6 months - 1 year).

AVAILABLE PACKAGES

Ferachel Forte 24 tablets

Ferachel Drops 50 ml

Efficacy and Safety of a New Formulation of Ferric Sodium EDTA Associated with Vitamin C, Folic Acid, Copper Gluconate, Zinc Gluconate (Ferachel forte) and Selenomethionine Administration in Patients with Secondary Anaemia. Curcio et al., J Blood Lymph 2018, 8:3 DOI: 10.4172/2165-7831.1000224: Study carried out in 114 patients with mild to severe iron deficiency anemia.

- The Ferric sodium EDTA complex (Ferrazone), Vitamin C, Folic Acid, Selenium, Zinc and Copper (Ferachel forte) can improve, with 1 tablet a day, the blood parameters (Hemoglobin, Ferritin and Serum Iron) and the anemia associated symptoms, with a high tolerability and a high satisfaction for the patients.

EFFICACY	T1 (values)	T2 (values)	T1 (average increase)	T2 (average increase)
Hb (g/dL)	+1.2	+2,2	+12%	+20%
Ferritin (mcg/dl)	+8.4	+18.9	+72%	+95%
Serum iron (mcg/dl)	+13.7	+33.4	+28%	+54%

T1: after 24 days of treatment

T2: after 72 days of treatment

Tolerability and Patient satisfaction			
Improvement in the symptomatology	Absence of side effects	Benefits	Symptoms of anemia (average value)
100% of patients	96% of patients	100% of patients	-78%

Study carried out by the “Sapienza” University of Rome, Italy - Hospital of Terracina
Marchitto et al. : Role of Sodium Fe++ EDTA associated with vitamin C, folic acid, Cu++ gluconate, Zn++ gluconate and Se++ methionine (FERACHEL forte) administration in patients with secondary anemia. Effects on hemoglobin value and cardiovascular risk.

- Improvement of lab values after 24 days:

Blood Parameter	Polysaccharide Fe++ intravenous 63 mg/die (into saline solution 500 ml)	Ferachel forte (2 tablets die)	Ferachel vs Polysaccharide Fe++ intravenous
HB (mg/dl)	9.9 + 1,9	11.7 + 1.9	+1.8
Fe++ (mg/dl)	37.1 + 21.9	53.8 + 25.9	+16,7

- Adherence to therapy;
- Statistically significant variation of the T-peak-to-T-end index, predictive parameter of cardiovascular risk, and onset of side effects (arrhythmic risk) due to a greater water supply and an high iron dilution into saline solution administered intravenously (Polysaccharide Fe++), in comparison with oral Sodium Fe++ EDTA.

Some more evidence-based literature:

- NaFe3 + EDTA: a new source of Fe3+, EDTA chelated, stable, tasteless, that does not cause gastrointestinal disorders;⁽¹⁾
- NaFe3 + EDTA: Increase of Hb (+13%), serum iron (+33%) and ferritin deposits (+70%) when compared to Ferrous Sulfate;^(4,6)
- Folic acid: + 23% of hemoglobin, of serum iron and of ferritin;⁽²⁾
- Vitamin C: + 400% of iron;⁽³⁾
- Copper: + 30% of iron;⁽⁴⁾
- Selenium and Zinc: + 23% of hemoglobin.^(5,6)

Bibliography

1. Alessandra Graziottin. Ferro (NaFe3+-EDTA), Lattoferrina, Vitamina C e Vitamina B12: sinergie farmacologiche: Per ottimizzare prevenzione e cura dell'anemia prima, durante e dopo la gravidanza.
2. Ai Guo Ma et al. Supplementation of iron alone and combined with vitamins improves haematological status, erythrocyte membrane fluidity and oxidative stress in anaemic pregnant women. British Journal of Nutrition (2010), 104, 1655-1661.
3. Hallberg L. et al. The role of vitamin C in iron absorption. Int J Vitam Nutr Res Suppl. 1989;30:103-8.
4. Reeves P.G. et al. Dietary Copper Deficiency Reduces Iron Absorption and Duodenal-Enterocyte Hephaestin Protein in Male and Female Rats. J Nutr. 2005, 135(1):92-8.
5. National Institutes of Health, Office of Dietary Supplements, (2006), "Dietary Supplement Fact Sheet: Selenium," <http://ods.od.nih.gov/factsheets/selenium.asp>
6. Phuong Nguyen, Ruben Grajeda, PaulMelgar, JessicaMarcinkevage,Rafael Flores ,Usha Ramakrishnan, and Reynaldo Martorell. Effect of Zinc on Efficacy of Iron Supplementation in Improving Iron and Zinc Status in Women. Journal of Nutrition and Metabolism, Volume 2012.
7. Marchitto N., Sindona F., Pannozzi A., Petrucci A., Fusco L, Dalmaso S., Raimondi G. Role of Sodium Fe++ EDTA associated with vitamin C, folic acid, Cu++ gluconate, Zn++ gluconate and Se++ methionine administration in patients with secondary anemia. Effects on hemoglobin value and cardiovascular risk.
8. Xiu X Han MD, Yong Y Sun MD, Ai G Ma MD, Fang Yang MD, Feng Z Zhang MD, Dian C Jiang MD, Yong Li. Moderate NaFeEDTA and ferrous sulfate supplementation can improve both hematologic status and oxidative stress in anemic pregnant women.
9. "Iron deficiency", by Nevin S. Scrimshaw, "Le Scienze (Scientific American)", No. 280, December 1991, page. 16-22.
10. Ovidio Brignoli, Italian society of General Medicine, "Anemia e terapia marziale. I dati di Health Search. Società Italiana di Medicina Generale".

Flavofort 1500®

Maximum concentration of the highest number of active substances with documented efficacy.

CLASSIFICATION

Food supplement based on Micronized Flavonoids, Plant Extracts Centella Asiatica, Blackberry, Red grapevine and Vitamin C.

NUTRITION FACTS (Tablets and sachets)

Ingredients	per dose 2 tablets	% NRV*
Micronized Diosmin	450 mg	-
Centella Asiatica p.e.	300 mg	-
Triterpene	60 mg	-
Micronized Hesperidin	270 mg	-
Vitis vinifera p.e.	200 mg	-
Proanthocyanidins	190 mg	-
Vitamin C	160 mg	200%
Vaccinium myrtillus p.e.	160 mg	-
Anthocyanosides	1,6 mg	-
Micronized Quercetin	140 mg	-
Micronized Rutin	130 mg	-

INGREDIENTS (cream)

Aqua, C12-15 alkyl benzoate, Caprylic/capric triglyceride, Cetareth-25, Cetyl alcohol, Glyceryl stearate, Isononyl isononanoate, Poloxamer 407, Glycerin, Propylene glycol, Cyclopentasiloxane, Carbomer, Phenoxyethanol, Sodium benzoate, Centella asiatica ower/leaf/stem extract, DMDM hydantoin, Glycine soja seed extract, Melilotus ofcinalis extract, Vaccinium myrtillus fruit/leaf extract, Glycyrrhetic acid, Disodium EDTA, Tocopheryl acetate, Maltodextrin, Menthyl lactate, PPG-25-laureth-25, Ethylhexylglycerin, PEG-40 hydrogenated castor oil, Cyclohexasiloxane, Sodium hyaluronate, Tetrasodium glutamate diacetate, Sodium hydroxide.

*VNR= Daily Reference Nutrition Value (Adult) (Reg. EU n.1169/2011)

CHARACTERISTICS

Flavofort 1500 was formulated to offer patients a product consisting of a mix of components at the highest concentration with documented scientific efficacy, reducing daily doses, thanks to the synergy of long-known active ingredients and their action on microcirculation. For the first time, this mix of active substances is presented in a single formulation. The value of flavonoids in association with other venotonics and venotrope substances for the management of venous insufficiency and associated symptoms.

INDICATIONS

Symptoms associated to venous insufficiency; capillary fragility; symptoms attributable to hemorrhoidal disease (tablets and sachets only).



Flavofort 1500®

HOW TO USE

- tablets: we recommend taking 1 to 2 tablets a day, with a glass of water.
- sachets: we recommend taking 1 sachet per day, with a glass of water. 1 sachet= 2 tablets
- cream: Apply in the morning and evening on the affected area.
Massage gently from bottom to top until completely absorbed.

The treatment must be continued for at least 30 days.

Treatment can also be performed for longer periods (6 months - 1 year).

AVAILABLE PACKAGES

30 tablets 1.25 g
14 sachets 3.5 g
30 sachets 3.5 g
Cream legs 150 ml

Evidence-based literature:

- Micronized Bioflavonoids: increased, improved absorption.

VENOUS INSUFFICIENCY:

RUTIN + DIOSMIN + HESPEREDIN

- Reduction of clinical signs and symptoms of chronic venous insufficiency and venous microangiopathies;
- Improvement of RAS (Rate of ankle swelling) in patients with CVI;^{2,8}

QUERCETIN

- Reduction of edema and leg volume;¹⁴
- 72% Reduction of leg volume in patients with CVI after administration of Quercetin;
- Reduction of the calf circumference after 12-week supplementation of Quercetin in patients with CVI;

CENTELLA ASIATICA

- 91% Reduction in ankle circumference in patients with CVI after administration of Centella asiatica;¹
- Resting of the skin blood flux at rest (RF) (microangiopathies) in patients with CVI after administration of Centella asiatica;¹

RED VINE

- Reduction of leg volume in patients with CVI after administration of red vine;⁸

VITAMIN C

- 71.6% Increase of the response of the skin microcirculation to ACh following the intake of Vitamin C;^{3,11}

HEMORRHOIDAL DISEASE:

DIOSMIN + HESPEREDIN + CENTELLA + FLAVONOIDS

- Decrease of hemorrhoids symptoms in 66% of patients with acute hemorrhoids as early as 4 days after beginning of administration of Diosmin + Hesperedin;⁴
- 100% Efficacy in decreasing bleeding and pain in patients with acute hemorrhoids after 7 days of Diosmin + Hesperedin administration;⁴
- 46% Reduction of rectal inflammation in patients with acute hemorrhoids after 7 days of Diosmin + Hesperedin administration.⁴

RUTIN + DIOSMIN + HESPEREDIN


- Reduction of clinical symptoms in patients undergoing hemorrhoidectomy surgery after 5 days of treatment;
- Reduction of hemorrhoidal symptoms after hemorrhoidectomy.

Flavofort 1500®

TOPICAL USE FLAVOFORT LEG CREAM

Flavofort leg cream: efficacy in reducing symptoms associated with venous insufficiency

Our study aims to evaluate Flavofort 1500® leg cream (Blackberry, Centella asiatica, Sodium Hyaluronate and Melilotus) in patients with chronic venous insufficiency and lower limb symptomatology, analyzing the improvement of symptoms, the time of effectiveness, the quality of the skin after treatment, the compliance of the product and the tolerability profile.



Method

35 patients with venous insufficiency and evident symptomatology associated with the lower limbs were recruited. In particular, 7 men and 28 women were recruited. 14% of the patients were aged between 26 and 35. 34% of the patients were aged between 36 and 50 and 52% of the patients were over the age of 50. -The patients that put Flavort 1500 leg cream on the affected area for a total of 10 days. The patients were evaluated 4 times: before treatment (T0), immediately after the first application (T1), 5 days after the treatment (T2) 10 days after the treatment (T3).

Evaluations carried out:

-T0: lower limb symptomatology associated with chronic venous insufficiency (fatigue and heaviness, swelling, diffuse pain, itching and tingling, nocturnal cramps, visible capillaries, reddening and dark spots, varicose veins); judgment on the quality of the skin (hydrated, luminous, elastic, soft or velvety).

-T1 and T2: symptomatology of the lower limbs.^{14,18}

-T3: lower limb symptomatology, assessment of skin quality and treatment compliance. At the end of the 10-day treatment, evaluations were made on the patients' judgment regarding the timing of treatment effectiveness and the pleasantness of the cream (texture, practicality and ease of use and overall judgment).

Conclusions

Treatment with Flavofort 1500® leg cream has led to a reduction of lower limb symptoms associated with chronic venous insufficiency in 100% of cases, in many patients in many patients after yet 5 days of application after 5 days of application of the cream.

Percentage reduction in patients with symptoms associated with venous insufficiency, after treatment with Flavofort 1500® cream legs.

SYMPTOMS	REDUCTION OF% PATIENTS WITH SPECIFIC SYMPTOM, AFTER TREATMENT
Tired and heavy legs	-85%
Widespread pain in the legs	-67%
Pruritus and tingling in the legs	-85%
Night cramps in the legs	-78%
Swelling in legs and ankles	-82%
Capillaries visible to the legs	-91%
Redness and dark spots on the ankles	-87%
Visibility and perceptibility of varicose veins	-100%

Table 2. *% of patients with reduced lower limb symptoms associated with venous insufficiency after treatment.

* The data shown are related to patients who assigned a 4 score to their symptoms, on a scale of 1 to 4 (1 = not at all, 2 = little, 3 = enough, 4 = a lot).

Flavofort 1500®

% increase of patients with smooth, soft, elastic, bright and hydrated skin after application of Flavofort 1500® leg cream.

SKIN CHARACTERISTICS	INCREASE OF PATIENTS% AFTER TREATMENT
Smooth	80%
Soft	88%
Elastic	91%
Bright	71%
Hydrated	63%

Table 3.% of patients with improvement of skin characteristics after treatment.

Opinion expressed by the patients about the cosmetic pleasantness of Flavofort 1500® cream legs.

Cosmetic pleasantness	Judgment expressed (Patients%)
The scent of cream ...	It leaves me indifferent (43%)
The product is absorbed ...	Normalmente/lentamente (43%)
The appearance of the product ...	I like it enough (51%)
The effects are visible after ...	5 days (40%)

Table 4. Opinion expressed by patients on the cosmetic pleasantness of the cream.

Bibliography

- Cesarone M.R. et al. Microcirculatory effects of total triterpenic fraction of *Centella asiatica* in chronic venous hypertension: measurement by laser Doppler, TcPO₂-CO₂, and leg volumetry. *Angiology* 52 Suppl 2:S45-48, 2001.
- Aguilar-Peralta G.R. et al. Clinical and capillaroscopic evaluation in the treatment of chronic venous insufficiency with *Ruscus aculeatus*, hesperidin methylchalcone and ascorbic acid in venous insufficiency treatment of ambulatory patients. *Int Angiol*. 26(4):378-384, 2007.
- Rabe et al. *Eur J Vasc Endovasc Surg* (2011) 41, 540e547.
- Marco Basile, Stefano Gidaro, Massimo Pacella, Paolo M. Biffignandi and Giacomo S. Gidaro Parenteral Troxerutin and Carbazochrome Combination in the Treatment of Posthemorrhoidectomy Status: A Randomized, Double blind, Placebo-controlled, Phase IV Study *Current Medical Research And Opinion* Vol. 17, No. 4, 2001, 256-261.
- Y.-H. Ho, C.L. Foo, F. Seow-Choen and H.S. GOH Prospective randomized controlled trial of a micronized flavonoidic fraction to reduce bleeding after haemorrhoidectomy *British Journal of Surgery* 1995, 82, 1034-1035.
- Galley P., Thiolet M.: A double-blind, placebocontrolled trial of a new veno-active fraction (S5682) in the treatment of symptomatic capillary fragility. *Int Angiol* 1993;12:69-72.
- Cesarone M.R., Belcaro G., Pellegrini L., Ledda A., Di Renzo A., Vinciguerra G., Ricci A., Gizzi G., Ippolito E., Fano F., Dugall M., Acerbi G., Cacchio M. H.R., O-(betahydroxyethyl)- rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study. *Angiology*. 2005 Jan-Feb;56(1):1-8.
- Kiesewetter H., Koscielny J., Kalus U., Vix J.M., Peil H., Petrini O., van Toor B.S., de Mey C. Efficacy of orally administered extract of red vine leaf AS 195 (*folia vitis viniferae*) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial. *Arzneimittelforschung*. 2000 Feb;50(2):109-17.
- Greeske K., Pohlmann B.K. Rosskastaniensamenextrakt-ein wirksames Therapieprinzip in der Praxis. *Fortschr Med* 1996; 114:196-200.
- Martinez-Zapata MJ, Vernooij RWM, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. *Cochrane Database Syst Rev*. 2016 Apr 6;4:CD003229. doi: 10.1002/14651858.CD003229.pub3. Review.
- Widmer LK. Pheripheral venous disorders: prevalence and socio-medical importance. Hans Huber, Bern 1978.
- Amisano GC, Amisano MF. Flebologia, da ieri al domani. L'insufficienza venosa ed una sua complicanza: "l'ulcera". Casa di Cura Salus, Alessandria.
- Scortecci V. Chirurgia generale - Patologia chirurgica per apparati. Raffaello Cortina Editore. Milano, 1996.
- Garreu C, Garreu Gomez B, Domenjou JM, Bianchi D, Portail M. Venous insufficiency and varicose disease. *Sequelae of lower limb thrombosis. The role of crenotherapy. Phlebologie*, 1993 Apr, Jun 46 (2):303-11.
- Nyuk Jet Chong and Zorah Aziz. A Systematic Review of the Efficacy of *Centella asiatica* for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency. *Evidence-Based Complementary and Alternative Medicine* Volume 2013, Article ID 627182, 10 pages <http://dx.doi.org/10.1155/2013/627182>.
- Ulbricht et al. An Evidence-Based Systematic Review of Bilberry (*Vaccinium myrtillus*) by the Natural Standard Research Collaboration. *Journal of Dietary Supplements*, Vol. 6(2), 2009.
- Assessment report for the development of community monographs and for inclusion of herbal substance(s), preparation (s) or combinations thereof in the list.

Medronys colesterolo®

Monacolin
K free

A new approach to managing dyslipidemia.

CLASSIFICATION: THERAPEUTIC SUBGROUP

Medronys cholesterol is a dietary supplement for adults based on Artichoke, Berberis, Fenugreek, Olive tree with Astaxanthin, Vitamin E, Folic acid, Chromium, Selenium, Zinc and Coenzym Q10.



NUTRITION FACTS

Per (maximum) daily dose (2 tablets)		%NVR*
Artichoke d.e. supply in chlorogenic acid	420 mg 21 mg	-
Berberis d.e. supply in berberine	200 mg 194mg	-
Fenugreek d.e.	200 mg	-
Astaxanthin	0,2 mg	-
Olive tree d.e. supply in oleuropein	100mg 40 mg	-
Chromium	60 mcg	150
Vitamin E	20 mg	167
Folic acid	400 mcg	200
Coenzyme Q10	10 mg	-
Selenium	83 mcg	150,9
Zinc	15 mg	150

*NVR= Daily Reference Nutrition Value (Adult) (Reg. EU n.1169/2011)

CHARACTERISTICS

Medronys cholesterol is a dietary supplement for adults based on Artichoke, Berberis, Fenugreek, Olive tree with Astaxanthin, Vitamin E, Folic acid, Chromium, Selenium, Zinc and Coenzym Q10.

Plant extracts: the artichoke maintains the normal metabolism of the lipids, berberis maintains the regular function of the cardiovascular system, the olive tree promotes the metabolism of carbohydrates and lipids, helps to maintain a normal blood circulation and the regularity of the arterial pressure, finally the fenugreek promotes the metabolism of carbohydrates, triglycerides and cholesterol.

Vitamins and minerals: Vitamin E and selenium protect cells from oxidative stress, folate contributes to normal homocysteine metabolism, zinc contributes to normal acid-base metabolism and fatty acids and carbohydrates. Chromium contributes to the metabolism of macronutrients and to the maintenance of normal levels of glucose in the blood. Astaxanthin and coenzyme Q10 complete the product composition.

INDICATIONS

Promotes the metabolism of cholesterol, carbohydrates and triglycerides.

It helps to maintain normal blood circulation and regularity of blood pressure.

HOW TO USE

1 to 2 tablets a day to be taken with a glass of water or other suitable liquid

1 package of 30 cps = 1 month of treatment.

Medronys colesterolo®

Available packages

-30 capsules

-60 capsules.



Medronys epato®

Liver recovery in a short time

CLASSIFICATION

Dietary supplement based on Milk thistle, Coenzyme Q10, Vitamin C, Vitamin E, Selenomethionine. Synergy of active ingredients with high concentration and documented scientific efficacy.

Nutrition declaration	Daily dosage (2 cps)	%DRVs°
Sylibum marianum	350 mg	
e.s.t. 80% in Silymarin*	280 mg	-
CoQ10	20 mg	-
Vitamin C	120 mg	150%
Vitamin E	40 mg	333%
Selenium	83 mcg	151%

*NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Medronys Epato is a product containing a powerful mix of high concentration active ingredients, whose efficacy is recognized in clinical practice. The product performs an antioxidant and activating action of the liver metabolic processes; it operates on the implications that an alteration of the hepatic metabolism generates both at the tissue and the blood level.

INDICATIONS

Indicated as supplement in the treatment of chronic liver diseases of different etiology, favoring the restoration of the physiological functions of the hepatocyte:

- Promotes liver detoxification processes
- Inhibits lipoperoxidation
- Promotes the maintenance of cellular functionality
- Promotes hepatic recovery in steatotic pathology.

HOW TO USE

1 to 2 tablets per day to be swallowed with plenty of water even after meals.
From 1 to 3 months or even for long periods (6 months - 1 year).



AVAILABLE PACKAGES

Medronys epato: 30 capsules

Medronys epato: 60 capsules

Study published on the Journal of gastrointestinal & digestive system. *The association of Silymarin, Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine for the treatment of non alcoholic fatty liver disease. Curcio A, Romano A, Pironti M, Di Nicola A, Grassi O, Schiaroli D, Nocera GF. Study carried out in 80 patients with mild to severe Non-Alcoholic Fatty Liver Disease (NAFLD).*

- The dietary supplement, composed by Silymarin, Vitamin C, Vitamin E, Coenzyme Q10, and Selenomethionine (Medronys epato) can improve with 1 or 2 capsules a day the blood parameters (ALT, AST, ALP, GGT and Ferritin) and the NAFLD associated symptoms, with a high tolerability and a high satisfaction for the patients.

	Medronys epato group® (n=80)			Placebo group (n=71)		
	T0 (Baseline)	T1 (45days)	T2(90 days)	T0 (Baseline)	T1 (45 days)	T2 (90 days) P value
Markers of liver damage - mean (± SD)						
ALT, U/L	71.6 (± 31.8)	52 (± 24.4)	39.4 (± 14.6)	82.4 (± 18.2)	83.6 (± 18.1)	78.7 (± 17.8)
AST, U/L	64 (± 30.4)	45.7 (± 21.2)	32.7 (± 11.4)	60.4 (± 10.5)	61.1 (± 10.2)	56.55 (± 10.3)
ALP, U/L	104.7 (± 13.2)	87.6 (± 53)	81.3 (± 54.8)	87.2 (± 12.9)	85.9 (± 3.8)	83.6 (± 13.6)
GGT, U/L	116.0 (± 17)	85.7 (± 24)	71.0 (± 29)	49.7 (± 9.2)	51.4 (± 9.2)	46.08 (± 8.7)
Ferritin, µg/L	116.0 (± 13)	105.4 (± 11)	93.6 (± 10)	234.5 (± 22)	346 (± 11.2)	340 (± 13.1)

Data are expressed as mean (± SD); ALT: Alanine Amino Transferase; AST: Aspartate Amino Transferase; ALP: Alkaline Phosphatase; GGT: Gamma-Glutamyl Transpeptidase; p value < 0.001, Medronys epato at T1 and T2 vs T0 (baseline); p value > 0.05, placebo at T1 and T2 vs T0 (baseline); a p value less than 0.05 is considered statistically significant.

Tolerability and Patient satisfaction		
Improvement in the symptomatology with benefits	Absence of side effects	Improvement of ultrasound
96% of patients	100% of patients	56% of patients (for 27.5%, the data was not reported)

Evidence-based literature:

LIVER DISEAS

- Silymarin: 60% reduction of ALT and 45% reduction of AST;¹
- Vitamin E and Vitamin C: improvement of fibrosis in patients with non-alcoholic steatohepatitis (NASH);²
- Coenzyme Q10: anti-inflammatory effect and 66% reduction of TNF (Tumor Necrosis Factor) in patients with NAFLD;³
- Silymarin e Selenomethionine: 19% reduction in LDL and 20% in cholesterol;⁴
- Silymarin: 34% increase in survival rate in patients with cirrhosis.⁵

Bibliography

- Hajaghamohammadi A., Ziaee A., Raei R. The efficacy of Silymarin in Decreasing Transaminase Activities in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. Hepatitis Monthly Sett. 2008.
- Stephen A. Harrison, Sigurd Torgerson, Paul Hayashi et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. The American Journal of Gastroenterology (2003).
- Ales Vidlara, Jitka Vostalovab, Jitka Ulrichovab et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy-a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Sep.
- Farsi F., Mohammadshahi M., Alavinejad P. et al. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr. 2015 Jul 9.
- P. Ferenci , B. Dragosics , H. Dittich. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul.
- Ales Vidlara, Jitka Vostalovab, Jitka Ulrichovab et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy-a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Sep.
- The Efficacy of Silybum marianum (L.) Gaertn. (Silymarin) in the Treatment of Type II Diabetes: A Randomized, Double-blind, Placebo-controlled, Clinical Trial.
- Paolisso G1, Balbi V, Volpe C, Varricchio G, Gambardella A, Saccomanno F, Ammendola S, Varricchio M, D'Onofrio F. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. J Am Coll Nutr. 1995 Aug;14.
- Ajda Skarlovnik, Miodrag Janic, Mojca Lunder Martina Turk, and Mišo Šabovic. Coenzyme Q10 Supplementation Decreases Statin-Related Mild-to-Moderate Muscle Symptoms: A Randomized Clinical Study. Med Sci Monit. 2014; 20: 2183-2188.

Proliset complex®

For a rapid resolution of the edema

CLASSIFICATION

Food supplement based on high concentration Bromelain, Papain and Zinc.

NUTRITIONAL VALUES

Ingredients	per dose 1 tablet	% NRV*
Bromelaine 2500 GDU/g	300 mg	-
Papain 100 TU/mg	200 mg	-
Zinc	10 mg	100

*NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Proliset Complex contains a potent mix of proteolytic enzymes (Bromelain and Papain) with a high concentration, associated with Zinc as their activator. These features make a product that is complete and quick in accomplishing the anti-edema and anti-inflammatory effect, allowing a fast recovery without any side effects. All of this is associated with the possibility of carrying out only one administration per day.

INDICATIONS


Indicated in edemigenous processes of inflammatory nature in surgical specialties and in general medicine, dentistry, gynecology, otorhinolaryngology. It also facilitates antibiotics absorption.

HOW TO USE

1 tablet on an empty stomach.

AVAILABLE PACKAGES

20 tablets 1.25 g



Evidence-based literature:

GENERAL MEDICINE

Speed up patients' recovery time: increase in antibiotic absorption:

- Bromelain + amoxicillin = + 103% amoxicillin tissue levels; + 40% amoxicillin blood levels;^{1,2,7}
- Tetracycline + bromelain = + 300% increase in tetracycline absorption;^{1,3}
- Papain + antibiotics such as benzylpenicillin, streptomycin, chloramphenicol, tetracycline, erythromycin and novobiocin: double efficacy.^{1,3}

Proliset complex®

DENTISTRY

- Anti-edema efficacy: + 38% compared to hydrocortisone; + 25% compared to acid acetylsalicylic acid;
- Reduction of remission time of edema to cut the time of dental intervention: double speed remission.¹¹

GYNECOLOGY

- Wounds resulting from episiotomy:¹⁰
 - 100% effectiveness in reducing edema and severe itching;
 - 92% effectiveness in reducing edema and severe pain at rest;
- Women suffering from breast engorgement:
 - reduction of swelling of the mammary glands.

OTORHINOLARYNGOLOGY

- Patients suffering from acute and chronic sinusitis: superior efficacy (+31%) in the resolution of edema and swelling of the nasal mucosa;
- Enhancement of antibiotic action and improvement of patients' ventilation;
- Reduction of edema and nasal swelling in 83% of treated patients;
- Patients suffering from soft tissue edema: healing in just 6 days.

Bibliography

1. Renzini G., Varengo M. The absorption of tetracyclin in combination with bromelain by oral application. *Arzneim-Forsch* 1972;22:410-412.
2. Gregory S. Kelly, N.D.: Bromelain: A Literature Review and Discussion of its Therapeutic Applications; *Alt Med Rev* 1996;1(4):243-257.
3. Baskanchiladze G.Sh., Khurtsilava L.A., Gelovani I.A., Asatiani M.V., Rossinskii V.I. Chemotherapeutic effectiveness of antibiotics in combination with papain in experimental septicemia-Antibiotiki. 1984 Jan;29(1):33-5.
4. Snowden H.M. et al. Treatments for breast engorgement during lactation. *Cochrane database of systematic reviews*. 2005, Issue 1, pp. 1-24.
5. Murata T. et al. The clinical effects of "protease complex" on postpartum breast engorgement. *J Jap Obstet Gynaecol Soc*. 1965;12(3), pp. 139-47.
6. Pavan R. et al. Properties and Therapeutic Application of Bromelain: A Review. *Biotechnology Research International*. 2012, Volume 2012, Article ID 976203, 6 pages.
7. Maurer H.R. Bromelain: biochemistry, pharmacology and medical use. *CMLS, Cell. Mol. Life Sci*. 2001, 58, pp. 1234-1245.
8. Howat R.C.L. and Lewis G.D. The effect of bromelain therapy on episiotomy wounds – A double blind controlled clinical trial. *J Obstetr Gynaecol BR Commonw*. 1972, 79, pp. 951-953.
9. Zatuchni G.I. and Colombi D.J. Bromelain therapy for the prevention of episiotomy pain.
10. *Obstetrics and Gynecology*. 1967, 29(2), pp. 275-278
11. Netti C., Bandi G.L., Pecile A.: Anti-inflammatory action of proteolytic enzymes of animal vegetable or bacterial origin administered orally compared with that of known anti-phlogistic compounds. *Farmaco Prat*. 1972 Aug;27(8):453-66.
12. Ryan R.E. A double-blind clinical evaluation of bromelains in the treatment of acute sinusitis. *Headache*. 1967, 7(1):13-7.
13. Tassman G., Zafran J., Zayon G. A double-blind crossover study of plant proteolytic enzymes of animal vegetable or bacterial origin administered orally compared with tat of known anti-phlogistic compounds. *Farmaco Prat*. 1972 Aug;27(8):453-66.
14. Luerti M, Vignali ML. Influence of bromelain on penetration of antibiotics in uterus, salpinx and ovary. *Drugs Expt Clin Res* 1978;4:45-48.
15. Baskanchiladze GSh, Khurtsilava LA, Gelovani IA, Asatiani MV, Rossinskii VI. Chemotherapeutic Effectiveness of antibiotics in combination with papain in experimental septicemia-Antibiotiki. 1984 Jan;29(1):33-5.
16. Neubauer R.A., "A plant protease for potentiation of and possible replacement of antibiotics" *Experimental Medicine and Surgery*, 1961, 19, pp. 143-160.

Proliset duo®

For targeted action on inflammatory processes.

CLASSIFICATION

Food supplement based on proteolytic enzymes Bromelain and Papain and on the flavonoids Quercetin and Hesperidin, with Zinc and Selenium.

NUTRITION FACTS

Composition	Amount (1 tablet)	% NRV°
Papain	200 mg 20000 TU	
Bromelain 2500 GDU (enzymatic activity)	300 mg 750 GDU	
Zinc	15 mg	150
Selenium	80 mcg	145
Quercetin	100 mg	
Hesperidin	100 mg	

°NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Proliset Duo was formulated to offer patients a product consisting of a mix of components at the highest concentration with documented scientific efficacy. The proteolytic enzymes bromelain and papain contained in Proliset Duo have synergistic effect in reduction of inflammation markers of the associated symptomatology. Bromelain and papain enhance antibiotics absorption, accelerating healing process. The addition of the flavonoids quercetin and hesperidin enhances bromelain and papain activities, contributing to the reduction of associated inflammatory symptoms through the draining effect typical of flavonoids.

The further presence of zinc and selenium contributes to protect the cells from oxidative stress and contribute to the normal function of the immune system. For the first time, this mix of active substances is presented in a single formulation.

The set of all the above-mentioned components in the same product ensuring a faster recovery in the case of moderate / severe edematous forms in dental, orthopedic and general surgical fields.

INDICATIONS

Indicated in case of inflammatory states of different nature and origin of which:

- orthopedic and traumatological inflammations (Bone fractures, post-operative hematomas);
- Myalgia, lumbago, torticollis, fibromyositis, bursitis, tendinitis, tenosynovitis, periarthritis, bruises, muscle sprains, sprains;
- acute and chronic inflammations of the nose and ear mucosa
- urological inflammations (prostatitis, cystitis);
- pre- and post-surgical inflammations of various kinds.

Useful as an adjunct to orthopedic and rehabilitative therapies.

HOW TO USE

The average recommended dose is one tablet a day to be swallowed with plenty of water, preferably without food.



AVAILABLE PACKAGES

15 tablets, 1250 mg

Evidence-based literature:

- Micronized Bioflavonoids: increased, improved absorption.
- Bromelain and papain enhance bioflavonoids absorption;
- Bromelain and papain enhance antibiotics absorption:
 - Bromelain + amoxicillin = + 103% amoxicillin tissue levels; + 40% amoxicillin blood levels;
 - Tetracycline + bromelain = + 300% increase in tetracycline absorption;
 - Papain + antibiotics such as benzylpenicillin, streptomycin, chloramphenicol, tetracycline, erythromycin and novobiocin: double efficacy.

GENERAL SURGERY

- Valid anti-inflammatory and antioxidant action through the effects on biomarkers of inflammation and of oxidative stress;²
- Inhibition of inflammatory cytokines expression through attenuation of NF-κB.
- Significant reduction of IL-1β (- 29.4%) and IL-8 (-28.3%), significant reduction of IL-6 (-12.4%), reduction of TNF-α (-7%).
- Consequent reduction of the inflammation time and stimulation of the immune system's response.
- Anti-edematous activity with slowing accumulation of liquids.
- Significant inhibition of induced-edema (90%) in rats, greater than diclofenac.
- Therapy with quercetin + bromelain + papain provides significant symptomatic improvement in men with chronic pelvic pain syndrome, acting on inflammation.⁹

DENTISTRY³

- Anti-edematous activity on serotonin-induced edema: + 38% compared to hydrocortisone; + 25% compared to acid acetylsalicylic acid;
- Reduction of healing time of edema after dental surgery: double speed remission.

ORTHOPEDY²

- Double efficacy of bromelain compared to escin in reducing edema and swelling of fractured limbs after surgery.
- Reduction with bromelain of signs of bruises and traumatic hematomas in less than 4 days in 78% of patients.
- Quercetin decreases (-50%) inflammation in induced-arthritis of rats.
- Efficacy of quercetin on inflammatory factors and clinical symptoms in women with rheumatoid arthritis.
- Hesperidine decreases (-33%) inflammation in induced-arthritis of rats.

Bibliography

1. Shokes D. A. et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. *Urology* 1999, 54 (6): 960-963.
2. Netti C. et al. Anti-inflammatory action of proteolytic enzymes of animal vegetable or bacterial origin administered orally compared with that of known anti-phlogistic compounds. *Farmaco Prat.* 1972 Aug; 27(8):453-66.
3. Tassman G., et al. A double-blind crossover study of plant proteolytic enzyme in oral surgery. *J Dent Med* 1965; 20:51-54.
4. Kameníček V., et al. Systemic enzyme therapy in the treatment and prevention of post-traumatic and postoperative swelling]. *Acta Chir Orthop Traumatol Cech.* 2001;68(1):45-9.
5. Blonstein J. Control of swelling in boxing injuries. *Practitioner* 1960, 203, pp. 206.
6. Luerti M. et al. Influence of bromelain on penetration of antibiotics in uterus, salpinx and ovary. *Drugs Expt Clin Res* 1978; 4:45-48.
7. Renzini G., Varengo M. The absorption of tetracyclin in combination with bromelain by oral application. *Arzneim-Forsch* 1972; 22: 410-412.
8. Gregory S. Kelly, N.D. Bromelain: A Literature Review and Discussion of its Therapeutic Applications; *Alt Med Rev* 1996;1(4):243-257.
9. Baskanchiladze G.Sh., et al. Chemotherapeutic effectiveness of antibiotics in combination with papain in experimental septicemia-Antibiotiki. 1984 Jan; 29(1):33-5.
10. Pendzhiev A.M. Proteolytic enzymes of Papaya: Medical applications. *Pharmaceutical Chemistry Journal*, 2002, Vol. 36, No. 6, 32-34.
11. MacKay D. and Miller A. Nutritional Support for Wound Healing *Alternative Medicine Review - Volume 8, Number 4 - 2003.*
12. Bahmani F. et al. The effects of selenium supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy: a randomised, double-blind, placebo-controlled trial. *British Journal of Nutrition* (2016), 116, 1222-1228.
13. Guardia T. et al. Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rat. *Il Farmaco* 2001; 56: 683-687.
14. Javadi F. M. The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial. *Journal of the American College of Nutrition* 2016: 1-7.

Proliset prost®

Maximum concentration of the highest number of active substances for a documented efficacy in prostatic and urological disorders.

CLASSIFICATION

Food supplement based on proteolytic enzymes Bromelain and Papain, on the flavonoid Quercetin, and with Serenoa repens, Zinc, Copper and Selenium.

Composition	Amount (1 tablet)
Serenoa repens	320 mg
Bromelain 2500 GDU/g	200 mg
Papain 100 TU/mg	100 mg
Quercetin	150 mg
Zinc	12 mg
Copper	2 mg
Selenium	0.083 mg

°NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Proliset prost was formulated to offer patients a product consisting of a mix of components at the highest concentration with documented scientific efficacy. The components of Proliset prost have synergistic anti-inflammatory and anti-oxidant activity, promoting the functionality of the prostate and of the urinary tract. Zinc, selenium and copper contribute to the protection of cells from oxidative stress; selenium contributes to normal spermatogenesis and zinc to normal fertility and normal reproduction.

Proliset PROST is able:

- to inhibit the enzyme 5-alpha reductase;
- to Inhibit the production of sex hormones, which represent replication inputs for prostate cells;
- to produce anti-estrogenic and antiandrogenic effects;
- to oppose the excessive cell proliferation of the parenchyma of prostate.

INDICATIONS

Indicated for the treatment of prostate disorders and benign prostatic hypertrophy-related symptoms. It is also useful for the treatment of male uro-genital diseases, thanks to the ability to promote the correct functioning of the prostate and of the urinary tract. Proliset prost is particularly suitable for adults starting from 40 years, and useful for the prevention of the disease.

HOW TO USE

We recommended taking 1 tablet a day with a glass of water, from 1 to 3 months.

AVAILABLE PACKAGES

30 tablets, 1200 mg



Evidence-based literature:

SERENOA REPENS¹

- Antiandrogenic, anti-inflammatory, and antiproliferative effects. These properties can inhibit the development and progression of LUTS/BPH (Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia);
- Lauric acid and linoleic acid contained in *S. repens* can inhibit the enzyme 5-alpha reductase leading to its antiandrogenic action;
- Downregulation of the prostate pro-inflammatory cytokine profile and reduction of the CCR7, CXCL6, IL-6, and IL-17 expression;
- Inhibition of several steps of prolactin receptor signal transduction, and thus, inhibition of the prolactin-induced prostate growth;
- More effective than tamsulosin in the reduction of inflammation biomarkers in LUTS/BPH patients in a clinical trial;
- Improvement of urologic symptoms and flow measures similar to finasteride with fewer adverse treatment events.

BROMELAIN²

- Analgesic properties in inflammatory pain and urogenital inflammation;
- Direct influence on pain mediators such as bradykinin, and indirect effects through anti-inflammatory actions which reduce pain;
- Enhancement of the effect of antibiotics;
- Enhance bioflavonoid component (quercetin) absorption.

PAPAIN³

- Valid anti-inflammatory action, with reduction of the inflammation time and with the stimulation of the immune system's response.

QUERCETIN⁴

- 37% improvement in symptoms of patients with chronic prostatitis;
- 40% reduction of pain symptoms of patients with chronic prostatitis;
- 39% improvement of quality of life in patients with chronic prostatitis;
- the 67% of treated patients with chronic prostatitis experimented benefits.

SELENIUM⁵

- Decrease of inflammation in chronic prostatitis;
- Reduction of prostate infection;
- Modulation of immune cell function through regulation of redox-sensitive transcription factors and influence on the production of cytokines and prostaglandins;
- Antioxidant and anti-inflammatory action, thanks to a) reduction of hydrogen peroxide, lipid, and phospholipid hydroperoxides b) reduction of the propagation of free radicals and reactive oxygen species and to c) reduction of hydroperoxide intermediates in the cyclooxygenase and lipoxygenase pathways, diminishing the production of inflammatory prostaglandins and leukotrienes.

SERENOA REPENS + SELENIUM⁶

- Synergistic efficacy on chronic prostatitis;
- 51.64% decrease in the total score related to the National Institutes of Health-Chronic Prostatitis Symptom Index in 8 weeks;
- 50.32% decrease of IPSS (International Prostate Symptom Score) in 8 weeks;
- 74% decrease in the urine white cell count.

SERENOA REPENS + BROMELAIN + SELENIUM⁷

- Improvement of the clinical efficacy of levofloxacin in patients affected by CBP (chronic bacterial prostatitis) without the development of side effects.

Proliset prost[®]

SERENOA REPENS + BROMELAIN + QUERCETIN⁶

- 37% Reduction of PSA (prostate specific antigen) in patients showing persisting level of PSA, greater than 4 ng/dl.

QUERCETIN + BROMELAIN + PAPAIN⁸

- The symptoms score improved from an average of 25.1 to 14.6 in patients with chronic prostatitis, representing a mean improvement of 44%.
- The 82% of the patients with chronic prostatitis demonstrated at least a 25% improvement in symptom score.

ZINC¹¹

- Activation of bromelain and papain. The presence of zinc is necessary for the correct function of proteolytic enzymes;
- Reduction of the volume of the prostate;
- Inhibition of the enzyme 5-alpha-hydroxylase which converts testosterone to DHT.

COPPER¹⁴

- Synergistic action with zinc;
- Protective antioxidant effect working to decrease the risk for development of prostate related issues.

COPPER + QUERCETIN¹⁵

- Higher antioxidant activity as compared to the pure quercetin. The metal ions (Cu[II]) significantly change the chemical properties of the quercetin.

Bibliography

1. Soo Liang Ooi et al. The Journal Of Alternative and Complementary Medicine 2017 Aug; 23(8):599-606.
2. Brien S. Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies. Evid Based Complement Alternat Med. 2004 Dec;1(3):251-257. Epub 2004 Oct 6.
3. Pendzhiev A.M. Proteolytic enzymes of Papaya: Medical applications. Pharmaceutical Chemistry Journal, 2002, Vol. 36, No. 6, 32-34
4. Shokes D. A. et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999, 54 (6): 960-963.
5. Kim H.W. et al. Preventive effect of selenium on chronic bacterial prostatitis. J Infect Chemother. 2012 Feb;18(1):30-4.
6. Morgia G. et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol Int. 2010; 84(4): 400-6.
7. Cai T. et al. Serenoa repens associated with selenium and lycopene extract and bromelain and methylsulfonylmethane extract are able to improve the efficacy of levofloxacin in chronic bacterial prostatitis patients. Arch Ital Urol Androl. 2016 Oct 5;88(3): 177-182.
8. Gallo L. The Effect of a Pure Anti-inflammatory Therapy on Reducing Prostate-specific Antigen Levels in Patients Diagnosed With a Histologic Prostatitis. Urology. 2016 Aug; 94:198-203.
9. MacKay D. and Miller A. Nutritional Support for Wound Healing Alternative Medicine Review - Volume 8, Number 4 - 2003.
10. Ebisch IM et al. The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Hum Reprod Update. 2007 Mar-Apr;13(2):163-74. Epub 2006 Nov 11. Review.
11. Feng P. et al. Direct Effect of Zinc on Mitochondrial Apoptogenesis in Prostate Cells. Prostate. 2002 September 1; 52(4): 311-318.
12. Khandrika L. et al. Role of Oxidative Stress in Prostate Cancer. Cancer Lett. 2009 September 18; 282(2): 125-136.
13. Fernandes A. S. Macrocyclic copper(II) complexes: Superoxide scavenging activity, structural studies and cytotoxicity evaluation. Journal of Inorganic Biochemistry 101 (2007) 849-858.
14. Bukhari S. B. et al. Synthesis, characterization and antioxidant activity copper-quercetin complex. Spectrochimica Acta Part A 71 (2009) 1901-1906.

Proliset sport®

Better performance in shorter times. Shorter times represent better performance.

CLASSIFICATION

Proliset Sport Before: Food supplement based on Micronized Flavonoids, plant extract Centella, Blackberry, Red grapevine, Vitamin C; **Proliset Sport After:** Bromelain, Papain and Zinc.

Proliset sport Before and After consists of two products in one package.

Proliset sport Before contains:		Proliset sport After contains:	
Micronized Diosmin 80%	225 mg	Bromelain 2500 GDU/g	300 mg
Micronized Rutin 80%	65 mg	Papain 100 TU/mg	200 mg
Micronized Hesperidin 95-98%	135 mg	Zinc	10 mg
Micronized Quercetin 98%	70 mg		
Vitis vinifera powder extract from which proanthocyanidins	100 mg 95 mg		
Vaccinium myrtillus powder extract from which anthocyanidins	80 mg 0.9 mg		
Centella asiatica (20% total triterpene) from which triterpene	150 mg 30 mg		
Vitamin C	80 mg		

°NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Blackberry, Centella and Red grapevine are beneficial for the functionality of microcirculation, reducing the feeling of heaviness of the legs.

Vitamin C contributes to the reduction of tiredness and fatigue, as well as contributing to the maintenance of the normal function of the immune system during and after intense physical exertion. Zinc contributes to the protection of the cell from oxidative stress and sustains the normal carbohydrate metabolism.

INDICATIONS

Proliset Sport helps prevent exercise-induced muscle damage. Facilitates muscle recovery and allows a faster restoration of contractile force, reducing tiredness and fatigue.

Indicated to improve the performance efficiency, to reduce fatigue, to speed recovery time.

Suitable for various types of sports such as: aerobic sports, cycling, running, team sports, water sports or anything else that requires effort and physical resistance.

HOW TO USE

We recommend the daily intake of one tablet of Proliset Sport Before, before a workout, and one tablet of Proliset Sport After, after the workout, with a glass of water.

AVAILABLE PACKAGES

20 Tablets 1100 mg + 20 tablets 1250 mg



Evidence-based literature

- MICRONIZED FLAVONOIDS: 38% increase in capillary resistance in patients with capillary fragility treated with Diosmin + Hesperidin;¹¹
- MICRONIZED FLAVONOIDS: variation in VO₂ max% as an indicator of the increase of the maximal aerobic capacity during exercise;³
- QUERCETIN: increases time to fatigue during the race;⁴
- QUERCETIN: improved performance assessed as an increase in mitochondrial activity and improved race time (+ 12 minutes);^{5,9}
- BROMELAIN, PAPAINE AND ZINC: Increased amount of proteases means a lower DOMS which turns into a rapid recovery, in the first 24 hours after the administration.⁹

Bibliography

1. Braun J.M., Schneider B., Beuth H.J. Therapeutic use, efficiency and safety of the proteolytic pineapple enzyme Bromelain-POS in children with acute sinusitis in Germany *In Vivo*. 2005 Mar-Apr;19(2):417-21.
2. Kerkhoffs G.M. et al. A double blind, randomised, parallel group study on the efficacy and safety of treating acute lateral ankle sprain with oral hydrolytic enzymes. *Br J Sports Med*. 2004, 38. pp. 431-435.
3. Davis JM, Carlstedt CJ, Chen S, Carmichael MD, Murphy EA. The dietary flavonoid quercetin increases VO₂(max) and endurance capacity. *Int J Sport Nutr Exerc Metab*. 2010 Feb;20(1):56-62.
4. Nieman DC et al. Quercetin reduces illness but not immune perturbations after intensive exercise. *Med Sci Sports Exerc*. 2007 Sep;39(9):1561-9.
5. Nieman DC et al. Quercetin's influence on exercise performance and muscle mitochondrial biogenesis. *Med Sci Sports Exerc*. 2010 Feb;42(2):338-45.
6. McAnulty SR, et al. Effect of mixed flavonoids, n-3 fatty acids, and vitamin C on oxidative stress and antioxidant capacity before and after intense cycling. *Int J Sport Nutr Exerc Metab*. 2011 Aug;21(4):328-37.
7. Bogucka-Kockaa, A., Wozniaka, M., Feldob, M., Kockic, J., Szewczyk, K., Diosmin -isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use. *Natural Product Communications* 2013; 8 (4): pp. 545-550.
8. A. Garg, S. Garg, L.J.D. Zaneveld and A.K. Singla, Chemistry and Pharmacology of The Citrus Bioflavonoid Hesperidin. *Phytother. Res*. 2001; 15, pp. 655-669.
9. Formica J.V. Review of the Biology of Quercetin and Related Bioflavonoids. *Fd Chem. Toxic*. 1995, Vol. 33, No. 12, pp. 1061-1080.
10. Agnes W. Boots et al. Health effects of quercetin: From antioxidant to nutraceutical. *European Journal of Pharmacology*, 2008, 585, pp. 325-337.
11. M. Harwood et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. *Food and Chemical Toxicology* 45 (2007) 2179-2205.
12. Ryszard Rutkowski et al. Vitamin C: is it time to re-evaluate its role in health and disease? *Postep. Derm. Alergol*. 2012; XXIX, 6: 456-460.
13. Garner R.C., Garner J.V., Gregory S., Whattam M., Calam A., Leong D. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. *J Pharm Sci*. 2002 Jan;91(1):32-40.
14. Galley P., Thiolet M.: A double-blind, placebocontrolled trial of a new veno-active fraction (S5682) in the treatment of symptomatic capillary fragility. *Int Angiol*1993;12:69-72.

Proliset vir®

Synergy and efficacy for disorders associated with erectile dysfunction.

CLASSIFICATION

Food supplement based on L-citrulline, Quercetin, Hesperidin, Griffonia, Tribulus, Maca, Korean Ginseng, Carnitine, Vitamin E, Vitamin C, Zinc, Copper, Selenium, Thiamine, Riboflavin, Niacin and Pantothenic acid.

NUTRITION FACTS

Nutrient	Quantity
L-citrulline	1500 mg
Quercetin	100 mg
Hesperidin	100 mg
Griffonia	50 mg
Tribulus	100 mg
Maca	100 mg
Korean ginseng root	100 mg
Carnitine	1000 mg
Vitamin E	18 mg
Vitamin C	150 mg
Zinc	7 mg
Copper	0,8 mg
Selenium	0,083 mg
Thiamine	1,1 mg
Riboflavin	1,400 mg
Niacin	16,000 mg
Pantothenic acid	6,000 mg

°NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Proliset VIR was formulated to offer patients a product consisting of a mix of components at the highest concentration with documented scientific efficacy. Its active components help to counteract disorders related to erectile dysfunction.

INDICATIONS

Treatment of disorders associated with erectile dysfunction. It also increases sexual desire and improves ejaculation and erection control.

HOW TO USE


2 sachets a day, 1 in the morning and 1 in the evening dissolved in a glass of water (150 ml).

Average cycles of 1 to 3 months are recommended.

For use as needed we recommend taking 2 sachets to be taken at intervals of 30 minutes approximately 1 hour and a half before the intercourse.

AVAILABLE PACKAGES

30 sachets 6 g



EVIDENCE-BASED LITERATURE

- L-citrulline improves erection in men suffering from mild erectile dysfunction. The beneficial effects of L-citrulline supplementation on erectile function resulted from an increase in corpus cavernosum L-arginine availability, leading to increased activity of mechanisms of vasodilation and penile smooth muscle relaxation.^{1,10}
- Tribulus stimulates sexual desire in patients with low to very low libido sexualis.¹¹
- Tribulus and Korean ginseng root are effective in erectile dysfunction and premature ejaculation.^{2,5}
- Antioxidant therapy with vitamin E ameliorates the age-associated erectile dysfunction.³
- Significant positive effect of maca on sexual dysfunction or sexual desire in healthy adult men.⁴
A significant improvement in psychological performance-related the Satisfaction Profile (SAT-P) scores in young adult patients with mild erectile dysfunction.¹²
- Quercetin ameliorates erectile dysfunction thanks to its antioxidant activity.⁶
- Niacin and carnitine may have a role as adjuvant therapy to PDE5i7,8. Niacin alone can improve the erectile function in patients suffering from moderate to severe ED and dyslipidemia.¹³
- Zinc is promising intervention for treating sexual dysfunction in chronic kidney disease (CKD).⁹

Bibliography

1. Cormio L, De Sisti M, Lorusso F, Selvaggio O, Mirabella L, Sanguedolce F, Carrieri G. Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction.
2. <https://reference.medscape.com/drug/asian-chinese-panax-ginseng-344462#2>
3. Helmy MM, Senbel AM. Evaluation of vitamin E in the treatment of erectile dysfunction in aged rats.
4. Shin BC, Lee MS, Yang EJ, Lim HS, Ernst E. Maca (*L. meyenii*) for improving sexual function: a systematic review.
5. Stasiak M, Żarłok K, Tomaszewski W. [Erectile dysfunction - treatment with substances of natural origin].
6. Zhang W, Wang Y, Yang Z, Qiu J, Ma J, Zhao Z, Bao T. Antioxidant treatment with quercetin ameliorates erectile dysfunction in streptozotocin-induced diabetic rats.
7. Gianfrilli D, Lauretta R, Di Dato C, Graziadio C, Pozza C, De Larichaudy J, Giannetta E, Isidori AM, Lenzi A. Propionyl-L-carnitine, L-arginine and niacin in sexual medicine: a nutraceutical approach to erectile dysfunction.
8. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging.
9. Vecchio M, Navaneethan SD, Johnson DW, Lucisano G, Graziano G, Querques M, Saglimbene V, Ruospo M, Bonifati C, Jannini EA, Strippoli GF. Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials.
10. Shiota A, Hotta Y, Kataoka T, Morita M, Maeda Y, Kimura K. Oral L-citrulline supplementation improves erectile function in rats with acute arteriogenic erectile dysfunction.
11. Neychev V, Mitev V. Pro-sexual and androgen enhancing effects of Tribulus terrestris L.: Fact or Fiction.
12. Zenico T, Cicero AF, Valmorri L, Mercuriali M, Bercovich E. Subjective effects of Lepidium meyenii (Maca) extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomised, double-blind clinical trial.
13. Ng CF, Lee CP, Ho AL, Lee VW. Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia.

Condroxol orto®

Synergy and efficacy in complete safety for the treatment of inflammatory diseases and associated pains

CLASSIFICATION

Condroxol orto® is a food supplement based on glucosamine, MSM, boswellia, bromelain, vitamin D, zinc, copper and selenium.

Ingredients	For dose/day in mg (2 tablets)	*%NRV
Glucosamin	300 mg	-
MSM	300 mg	-
Boswellia	600 mg	-
Boswellia acids	390 mg	-
Bromelain	400 mg	-
Zinc	12.5 mg	124
Selenium	80 mcg	146
Copper	1.8 mg	180
Vitamin D	20 mcg	400

*NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Condroxol Orto is a product containing a powerful mix of active ingredients with a high concentration, whose efficacy is recognized in clinical practice. Condroxol Orto is a natural anti-inflammatory with mild analgesic action used in non-acute conditions associated with the different kinds of osteoarticular traumas. Indicated for the treatment of inflammatory joint diseases.

INDICATIONS

In inflammatory joint diseases and specifically:

- in physical medicine and rehabilitation to facilitate recovery in shorter times and to improve the quality of physiotherapy;
- in different kinds of osteoarticular traumas, also associated with sports activities;
- joint overload;
- in the pre and post-operative inflammatory response;

HOW TO USE

We recommend taking one tablet twice a day, with one tablet taken in the morning and one in the evening, for about 3 months.

AVAILABLE PACKAGES

Condroxol Orto 24 tablets



Condroxol orto®

Evidence-based literature

METHYLSULFONYLMETHANE:^{2,3}

- -35% reduction of joint stiffness;
- -58% reduction of pain symptoms;

GLUCOSAMINE AND METHYLSULFONYLMETHANE:

- -73% reduction of osteoarticular symptomatology;^{1,4}
- +25% improvement of bone function;
- double efficacy in reducing osteoarthritis symptoms;

BOSWELLIA:⁶

- -56% reduction of osteoarticular pain;
- +36% improvement of bone health (reduction of pain and degree of disability);
- -28% reduction of lower back and knee pain;

BROMELAIN VS NSAIDS:⁵

- -25% pain reduction;
- patients with contusions and hematomas: reduction of signs of ecchymosis in less than 4 days in 78% of treated patients;

SELENIUM + VITAMIN D + COPPER:⁷

- +30% bone strength improvement.

Bibliography

1. Drovanti A, et Al. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo-controlled, double blind investigation. *Clinical Therapeutics*, 1980; 3 (4): 260-272.
2. Noriyuki Kanzaki, 1 Yuta Otsuka, 1 Takayuki Izumo, 1 Hiroshi Shibata, 1 Hideyuki Nagao, Axelrod, N.D. (Professor), Dr P. Howard, M.D. (Medical Director), Dr N. Buratovich, N.D. (Chair), Dr R.F. Waters, Ph.D. (Chair).
3. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study-Eytan M. Debbi*†, Gabriel Agar, Gil Fichman, Yaron Bar Ziv, Rami Kardosh, Nahum Halperin, Avi Elbaz, Yiftah Beer and Ronen Debi.
4. Usha P.R., Naidu MUR. Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis. *Clinical Drug Investigation* 24 (6): 353-363, 2004.
5. Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies Sarah Brien,* George Lewith, Ann Walker, Stephen M. Hicks, and Dick Middleton.
6. Management of osteoarthritis (OA) with the pharma-standard supplement FlexiQule (Boswellia): a 12-week registry. Belcaro G, Dugall M., Luzzi R., Ledda A., Pellegrini L., Hu S., Ippolito E
7. Copper, iron, and selenium dietary deficiencies negatively impact skeletal integrity: A review-Medeiros DM.

Condroxol artro®

A new approach to arthritis therapy and related cartilage degeneration

CLASSIFICATION

Condroxol Artro® is a food supplement based on Glucosamine, Chondroitin Sulfate, Hydrolyzed Collagen, Methylsulfonylmethane (MSM), Vitamin E and Devil's claw.

NUTRITIONAL INFORMATION

	For dose (1300 mg)	%NRV*	Dose max die (2600 mg)	%NRV*
Glucosamine	200 mg	-	400 mg	-
Chondroitin Sulfate	200 mg	-	400 mg	-
Harpagophytum procumbens (tit. to 2,5% of arpagoside)	200 mg	-	400 mg	-
Methylsulfonylmethane	100 mg	-	200 mg	-
Hydrolyzed Collagen	100 mg	-	200 mg	-
Vitamin E	18 mg	150	36 mg	300

NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Condroxol artro® is a product containing a powerful mix of high concentration active ingredients, whose efficacy is recognized in clinical practice. Condroxol artro stimulates the repair of articular cartilage, protects cartilage from free radicals damage and decreases osteoarthritis symptoms.

Devil's claw favors joint function; vitamin E protects cells from oxidative stress.

INDICATIONS

Indicated for treatment of cartilage's degeneration and for pain by mechanical stress.

HOW TO USE

We recommend 1-2 tablets a day, with a glass of water or other suitable liquid.

AVAILABLE PACKAGES

Condroxol Artro® 20 tablets



Evidence-based literature

GLUCOSAMINE:¹

- -36% reduction of knee pain;

METHYLSULFONYLMETHANE:^{2,3}

- -35% reduction of joint stiffness;
- -58% reduction of pain symptoms;

GLUCOSAMINE AND METHYLSULFONYLMETHANE:⁴

- -73% reduction of osteoarticular symptomatology;
- +25% improvement of bone function;
- double efficacy in reducing osteoarthritis symptoms.

Condroxol artro®

CHONDROITIN SULFATE + GLUCOSAMINE:^{7,8}

- 50.1% decrease of WOMAC (Western Ontario and McMaster osteoarthritis index score) moderate-to-severe pain;
- reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion.

DEVIL'S CLAW/ARPAGOSIDE:⁶

- as effective as diacerhein (p=0.001) and with significantly fewer side-effects (p=0.042);
- pain reduction compared with placebo at both 30 days (p=0.018) and 60 days (p=0.012).

HYDROLYZED COLLAGEN:¹¹

- stimulates a statistically significant increase in synthesis of extracellular matrix macromolecules by chondrocytes (p < 0.05 compared with untreated controls);
- 75% of patients demonstrated improvement: 45% of patients were symptom free and 30% had clearly improved symptoms after a 3-month treatment;

VITAMIN E:^{9,10}

- malondialdehyde, a highly reactive compound, (Group A 1.34 ± 0.10 , Group B 1.00 ± 0.09 , p < 0.02), α -Tocopherol (Group A 15.92 ± 1.08 , Group B 24.65 ± 1.47 , p < 0.01) and Trolox Equivalent Antioxidant Capacity (Group A 4.22 ± 0.10 , Group B 5.04 ± 0.10 , p < 0.01) were significantly different between Group A/placebo and Group B/Vit. E supplementation;
- WOMAC score (Stiffness, Pain, Function) was significantly improved;
- fewer synovial tissue cells were stained with nitrotyrosine and hematoxylin-eosin, indicator of cell damage and inflammation.

Bibliography

1. Drovanti A, et Al. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo-controlled, double blind investigation. *Clinical Therapeutics*, 1980; 3 (4): 260-272.
2. Noriyuki Kanzaki, 1 Yuta Otsuka, 1 Takayuki Izumo, 1 Hiroshi Shibata, 1 Hideyuki Nagao, Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial Dr L.S. Kim, N.D.†, (Medical Director), Dr L.J. Axelrod, N.D. (Professor), Dr P. Howard, M.D. (Medical Director), Dr N. Buratovich, N.D. (Chair), Dr R.F. Waters, Ph.D.¶ (Chair).
3. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study-Eytan M. Debbi*†, Gabriel Agar, Gil Fichman, Yaron Bar Ziv, Rami Kardosh, Nahum Halperin, Avi Elbaz, Yiftah Beer and Ronen Debi.
4. Usha P.R., Naidu MUR. Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfoylmethane and their Combination in Osteoarthritis. *Clinical Drug Investigation* 24 (6): 353-363, 2004.
5. Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies Sarah Brien, 1,* George Lewith, 1 Ann Walker, 2 Stephen M. Hicks, 2 and Dick Middleton 3.
6. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip. Chrubasik S. 1, Thanner J., Künzel O., Conrad C., Black A., Pollak S
7. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Marc C Hochberg, Johanne Martel-Pelletier et al.
8. J Altern Complement Med. 2006 Dec;12(10):981-93. Devil's Claw (Harpagophytum procumbens) as a treatment for osteoarthritis: a review of efficacy and safety. Brien S, Lewith GT, McGregor G.
9. Effect of vitamin E on oxidative stress level in blood, synovial fluid, and synovial tissue in severe knee osteoarthritis: a randomized controlled study. Saran Tantavisut, Aree Tanavalee, et al.
10. Saudi Med J. 2009 Nov;30(11):1432-8. Palm vitamin E and glucosamine sulphate in the treatment of osteoarthritis of the knee. Haflah NH, Jaarin K, Abdullah S, Omar M.
11. Curr Med Res Opin. 2006 Nov;22(11):2221-32. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Bello AE, Oesser S.

Condroxol nerv®

Rapidity and effectiveness in the treatment of peripheral neuropathies

CLASSIFICATION

Condroxol nerv® is a dietary supplement based on plant Glucosamine, Methylsulfonylmethane (MSM), Alpha lipoic acid (ALA), Acetyl-L-carnitine (ALC), Vitamin E, Niacin (Vitamin PP or B3), Vitamin B6, B2, B1 and B12, useful in cases of reduced intake or increased need for these nutrients.

NUTRITIONAL INFORMATION

	For dose/day in mg (2 tablets)	%NRV*
Plant Glucosamine	400 mg	-
Methylsulfonylmethane	200 mg	-
Alpha lipoic acid MATRIS®	400 mg	-
Acetyl-L-carnitine MATRIS®	200 mg	-
Vitamin E	36 mg	-
Niacin (Vit. PP or B3)	36 mg	-
Vitamin B6	9.5 mg	-
Vitamin B2	25 mg	-
Vitamin B1	25 mg	-
Vitamin B12	0.02 mg	200

NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Condroxol nerv® is a product containing a powerful association of multiple active ingredients with different mechanisms (multimodal therapy), whose efficacy is recognized in clinical practice. Condroxol nerv® is a natural anti-inflammatory and a strong antioxidant, with a decent analgesic action that relieves neuropathic pain. It contains Alpha lipoic acid and Acetyl-L-carnitine in *matrix retard*. The low bioavailability of alpha-lipoic acid is overcome in Condroxol nerv®: ALA, ALC also, is enclosed within a matrix, which guarantees a better absorption (+85%), over 8 hours.

INDICATIONS

Indicated for treatment of peripheral neuropathies.

Peripheral neuropathies are chronic diseases of the peripheral nervous system, associated with CNS neuro-inflammation; they result from a deterioration and malfunctioning of the peripheral nerves.

The most common cause is diabetes mellitus; other origins include also vitamin deficiencies, medication (e.g., chemotherapy, or commonly prescribed antibiotics), genetic diseases, excessive alcohol consumption, immune system diseases and traumas.

HOW TO USE

We recommend taking 2 tablets a day, to be swallowed with plenty of water, away from meals.

AVAILABLE PACKAGES

Condroxol nerv 30 capsules. Net weight 22.5 g.



Condroxol nerv[®]

Evidence-based literature

GLUCOSAMINE:¹

- statistically significant 17% reduction in hs-CRP levels, as compared with non-use;
- reduced PGF2 α concentrations (p-trend: 0.01): 40% lower adjusted geometric mean PGF2 α , than non-users;
- lower levels of oxidative stress and anti-inflammatory effects resulting from inhibition of nuclear factor kappa B (NFkB) activity;

METHYLSULFONYLMETHANE:

- -58% reduction of pain symptoms;

GLUCOSAMINE AND METHYLSULFONYLMETHANE:

- -73% reduction of symptomatology;
- double efficacy in reducing pain and CIPN symptoms;

ALPHA LIPOIC ACID:²

- IL-1 α ($-9.9\% \pm 3.7$, $P = 0.013$) and IL-6 ($-26.5\% \pm 8.2$, $P = 0.003$) significantly decreased;
- 50% reduction in TSS (Total Symptom Score) after 5 weeks of administration;

ALPHA LIPOIC ACID + VITAMIN B1:

- normalization of hyperglycemia;
- normalization of prostacyclin synthase suppressed by diabetes after 4 weeks of administration;
- increase of TK activity in monocytes after 2-3 times;
- clinically significant improvements in pain, burning, parasthesias, and numbness

ALPHA LIPOIC ACID + METHYLSULFONYLMETHANE:

- analysis of Visual Analog pain Scale (VAS) data showed a progressive reduction (36%) in pain perceived; NCI-CTC sensor and motor score, mISS scale and TNSc scale, both pain and both sensor and motor neuropathic impairment decreased after 12 weeks of treatment;

ACETYL-L-CARNITINE:⁸

- 92% improvement of TNS (Total neuropathy score);
- statistically significant decrease in lipoprotein(a) [Lp(a)] levels;
- positive effects on nervous parameters in a combined lipid analysis of two phase III clinical studies;

VITAMIN E:^{6,7}

- lower neurotoxicity in the patient groups who received vitamin E supplementation (25%) as compared to the control group (73%);
- positive effects on two electrophysiological parameters in a phase II study;

NIACIN (VIT. PP OR B3):^{11,12}

- higher levels (50%) of NAD⁺ which protects against nerve damage
- increased NAD (50%), a critical cofactor for mitochondrial oxidative phosphorylation systems and cellular redox systems involved with energy metabolism and fuel utilization;

B COMPLEX VITAMINS (B1, B6, B2 AND B12)¹³

- promotion of nerve repair, both in acceleration of nerve tissue regeneration and recovery of nerve function by inhibition of cerebral oxidative stress;
- 71% clinically significant improvement in burning pain, numbness and paresthesia.
- whole-brain atrophy rate per year was 29.6% less in the study group (0.76%, 95% CI 0.63-0.90) than the placebo.

Bibliography

1. Usha P.R., Naidu MUR. Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis. *Clinical Drug Investigation* 24 (6): 353-363, 2004.
2. Diabetes Care. 2006 Nov;29(11):2365-70. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, -Samigullin R.-Maedica (Buchar). 2013 Jun;8(2):137-42. The consumption of alanerv® nutritional supplement and the dynamic of some inflammatory markers in post-acute stroke patients undergoing rehabilitation. Cinteza D, Berteanu M, Vladoiu S, Manolescu BN, Dinu H.
3. Association Between Use of Specialty Dietary Supplements and C-Reactive Protein Concentrations Elizabeth D. Kantor*, Johanna W. Lampe, Thomas L. Vaughan, Ulrike Peters, Colin D. Rehm, and Emily White
4. Victoria A Serhiyenko, Alexandr A Serhiyenko. Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
5. Putting Evidence Into Practice®: Evidence-Based Interventions for Chemotherapy-Induced Peripheral Neuropathy. Constance Visovsky, PhD, RN, ACNP, Mary Collins, MSN, RN, OCN®, Linda Abbott, RN, MSN, AOCN®, CWON, Julie Aschenbrenner, RN, BSN, OCN®, and Connie Hart, BSN, RN, OCN®.
6. Vitamin E for prophylaxis against chemotherapy-induced neuropathy A randomized controlled trial A. A. Argyriou, E. Chroni, A. Koutras, J. Ellul, S. Papapetropoulos, G. Katsoulas, G. Iconomou and H. P. Kalofonos.
7. Vitamin E Reduces Cisplatin Ototoxicity. James G. Kalkanis, MD; Craig Whitworth, MA; Leonard P. Rybak, MD, PhD.
8. Eur J Cancer. 2005 Aug;41(12):1746-50. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L.
9. Specialty supplement use and biologic measures of oxidative stress and DNA damage Elizabeth D. Kantor, Cornelia M. Ulrich, Robert W. Owen, Peter Schmezer, Marian L. Neuhaus, Johanna W. Lampe, Ulrike Peters, Danny D. Shen, Thomas L. Vaughan and Emily White.
10. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study q N.I. Weijl a, T.J. Elsendoorn a, E.G.W.M. Lentjes b, G.D. Hopman c, A. Wipkink-Bakker c, A.H. Zwinderman d, F.J. Cleton a, S. Osanto.
11. Nicotinamide riboside (vitamin B3) prevents nerve pain caused by cancer drugs. University of Iowa Health Care.
12. Pain. 2017 May;158(5):962-972. doi: 10.1097/j.pain.0000000000000862. Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. Hamity MV1, White SR, Walder RY, Schmidt MS, Brenner C, Hammond DL.
13. B Vitamins for Neuropathy and Neuropathic Pain Mauro Geller1, Lisa Oliveira1, Rafael Nigri1, Spyros GE Mezitis2, Marcia Gonçalves Ribeiro3, Adenilson de Souza da Fonseca4, Oscar Roberto Guimarães5, Renato Kaufman6 and Fernanda Wajnsztajn
14. J Inherit Metab Dis. 2016; 39: 559-564. Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience Bregje Jaeger and Annet M.
15. J Nutr Health Aging. ARE DIETARY SUPPLEMENTS AND NUTRACEUTICALS EFFECTIVE FOR MUSCULOSKELETAL HEALTH AND COGNITIVE FUNCTION? A SCOPING REVIEW. G. IOLASCON et al.
16. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. *PLoS One* 2010;5(9):e12244. doi: 10.1371/journal.pone.0012244.

Condroxol osteo®

All you need for your bone health.

CLASSIFICATION

Condroxol OSTEO® is a dietary supplement based on Calcium Carbonate, Magnesium Carbonate, Vitamin D, Vitamin C, Vitamin K, Manganese, Soy Isoflavones, Methylsulfonylmethane, *Equisetum arvense* extract, Zinc, Copper and Selenium.

NUTRITIONAL INFORMATION

	For dose/day in mg (3 tablets)	*%NRV
Calcium carbonate	600 mg	75
Magnesium carbonate	75 mg	20
Vitamin C	300 mg	375
Methylsulfonylmethane	150 mg	
Soy (tit. to 40% of Isoflavones)	100 mg 40 mg	
Zinc	12.5 mg	125
Equisetum arvense (tit. to 2% of silicon)	60 mg 1.2 mg	
Vitamin K	105 mg	140
Manganese	10 mg	500
Selenium	83 mg	151
Vitamin D	25 mg	498
Copper	1.3 mg	130

NRV = Nutrient Reference Value (adults) - Reg. (EU) No. 1169/2011

CHARACTERISTICS

Condroxol osteo contains a powerful mix of active ingredients, whose efficacy is recognized in clinical practice. It is a product made with hypoallergenic, vegetarian ingredients, that help provide osteoporosis support and delivers optimal oligoelements absorption to support bone density, and bone health in general. The silicon in horsetail (*Equisetum arvense*) has an effect on bone growth processes, most likely through affecting collagen turnover; also it enhances the bone elasticity. On the other hand, soy isoflavones have positive effects on BMD (Bone Mineral Density) and bone turnover markers in menopausal women. Copper is required in the cross-linking of collagen and elastin, Manganese in the biosynthesis of mucopolysaccharides for an optimal organic matrix formation. Zinc improves osteoblastic activity, collagen and chondroitin sulfate synthesis and alkaline phosphatase activity.

INDICATIONS

Indicated for the treatment of osteoporosis and to keep bones and teeth strong and in good health.

HOW TO USE

We recommend taking 1-3 tablets a day depending on the severity of the illness, with a glass of water, during meals.

AVAILABLE PACKAGES

Condroxol osteo® 45 tablets

Condroxol osteo®



Condroxol osteo® 45 tablets

Evidence-based literature

CALCIUM CARBONATE:¹

- 5.2% reduction in the incidence of osteoporotic fractures;
- 3.3% reduction in the incidence of vertebral deformity;
- 45% increase in BMC (Bone Mineral Content) of the femoral neck;
- 52% increase in BMC of the whole body, with calcium carbonate 600 mg 2 times a day;
- 7.2% increase in BMD (Bone Mineral Density) of lumbar spine;
- 2.1% increase in BMD of the hip, with calcium carbonate 1800 mg/day;
- 6% increase in BMD of the femoral neck
- 5.8% increase of the total amount of calcium in the body, with calcium carbonate 1700 mg / day.

CALCIUM CARBONATE + VITAMIN D:^{1,3}

- 16% reduction in the incidence of osteoporotic fractures with calcium carbonate 1000 mg/day and vitamin D 10 mcg/day.

MAGNESIUM CARBONATE:²

- Increase of 0.04 g/cm² in women and 0.02 g/cm² in men of total body BMD, with greater impact on women who are the most likely people to develop osteoporosis.

METHYLSULFONYLMETHANE:¹⁴

- -35% reduction of joint stiffness;
- -58% reduction of pain symptoms.

SOY ISOFLAVONES:

- increasing lumbar spine BMD by 20.3-21.3 mg/cm²;
- decreases bone resorption urine DPD (- 17-18%).

EQUISETUM ARVENSE/SILICON:

- mineral apposition and bone formation rate was 30% greater, in ovariectomized rats;
- less bone resorption;
- collagen type 1 synthesis increased, at orthosilicic acid concentrations of 10 and 20 µM (1.8-fold, p < 0.001), in human osteoblast-like cells;
- alkaline phosphatase activity and osteocalcin were significantly increased (1.5, 1.2-fold, respectively, p < 0.05), in human osteoblast-like cells.

SELENIUM + VITAMIN D + COPPER:

- +30% bone strength improvement.

Condroxol osteo®

COPPER + MANGANESE + ZINC + CALCIUM CARBONATE:^{6,9,10}

- changes in spinal BMD from baseline ($p = 0.036$), in the 3rd and 6th months of therapy.

VITAMIN C:⁴

- decrease of lipoperoxides (LPO) ($p < 0.05$), linked with hip bone loss, versus the placebo group, for a 12-month period of treatment.

VITAMIN K:

- significantly improves bone health in the study group compared with placebo ($p = 0.023$ for BMC; $p = 0.014$ for BMD), after a 3-year supplementation. Statistically significant difference in both impact;
- significantly improves strength index (ISI) ($p < 0.05$) and compression strength index (CSI) ($p = 0.022$ after 2 years; $p = 0.075$ after 3 years).

Bibliography

1. US FDA Part 184 -Direct food substances affirmed as generally recognized as safe - Subpart B-Listing of Specific Substances Affirmed as GRAS Sec. 184.1191 calcium carbonate: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=184.1191>.
2. US FDA Part 184 -Direct food substances affirmed as generally recognized as safe - Subpart B -Listing of Specific Substances Affirmed as GRAS Sec. 184.1425 Magnesium carbonate: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=184.1425>.
3. US FDA PART 172 -Food additives permitted for direct addition to food for human consumption - Subpart D -Special Dietary and Nutritional Additives Sec. 172.380 Vitamin D [bdi3]: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=172.380>.
4. Select Committee on GRAS Substances (SCOGS) Opinion: L-ascorbic acid: <https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260452.htm>
5. GRAS Notices GRN No. 245: <https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=grasnotices&id=245>
6. US FDA Part 184 -Direct food substances affirmed as generally recognized as safe - Subpart B -Listing of Specific Substances Affirmed as GRAS Sec. 184.1461 Manganese sulfate: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=184.1461> - Sec. 184.1452 Manganese gluconate: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=184.1452>
7. GRAS Notification for Isoflavones Derived from Soybeans: <http://wayback.archive-it.org/7993/20171031055001/https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm264301.pdf>
8. Agency Response Letter GRAS Notice No. GRN 000229: <https://wayback.archive-it.org/7993/20171031015431/https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm153891.htm>
9. US FDA PART 182 -Substances generally recognized as safe - Subpart I -Nutrients Sec. 182.8991 Zinc oxide: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=182.8991> - Sec. 182.8997 Zinc sulfate: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=182.8997>
10. Select Committee on GRAS Substances (SCOGS) Opinion: Copper (cupric) gluconate, Copper (cupric) sulfate, Cuprous iodide: <https://wayback.archive-it.org/7993/20171031061331/https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm261260.htm>
11. GRAS Notices GRN No. 260: <https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=grasnotices&id=260>
12. Linee guida per la prevenzione dell'osteoporosi, Ministero della Salute, http://www.salute.gov.it/imgs/C_17_pagineAree_1464_listaFile_itemName_0_file.pdf
13. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial Dr L.S. Kim, N.D.†, (Medical Director), Dr L.J. Axelrod, N.D. (Professor), Dr P. Howard, M.D. (Medical Director), Dr N. Buratovich, N.D. (Chair), Dr R.F. Waters, Ph.D.¶ (Chair).
14. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study-Eytan M. Debbi*†, Gabriel Agar, Gil Fichman, Yaron Bar Ziv, Rami Kardosh, Nahum Halperin, Avi Elbaz, Yiftah Beer and Ronen Debi.
15. J Nutr Health Aging. 2007 Mar-Apr; 11(2): 99–110. SILICON AND BONE HEALTH R. JUGDAOHSINGH.
16. Dietary Silicon Affects Bone Turnover Differently in Ovariectomized and Sham-Operated Growing Rats Forrest H. Nielsen* and Rhonda Poellot.
17. Silicon: A Review of Its Potential Role in the Prevention and Treatment of Postmenopausal Osteoporosis Charles T. Price, Kenneth J. Koval, and Joshua R. Langford Orlando Health Department of Orthopedic Surgery, 1222 Orange Avenue, Orlando, FL 32806, USA.
18. Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro D.M. Reffitt, N Ogston, R Jugdaohsingh, H.F.J. Cheung, B.A.J. Evans, R.P.H. Thompson, J.J. Powell, G.N. Hampson.
19. Soy isoflavones for osteoporosis: An evidence-based approach Kyoko Takua, Melissa K. Melby b, Nobuo Nishi c, Toyonori Omori d, Mindy S. Kurzer e
20. The role of trace minerals in osteoporosis. P D Saltman & L G Strausea Dept. of Biology, University of California San Diego, La Jolla 92093. Published online: 27 Aug 2013.
21. J Bone Miner Metab. 2002;20(1):39-43. The role of trace minerals in the pathogenesis of postmenopausal osteoporosis and a new effect of calcitonin. Gür A, Colpan L, Nas K, Cevik R, Saraç J, Erdoğan F, Düz MZ.
22. J Nutr Health Aging. Are dietary supplements and nutraceuticals effective for musculoskeletal health and cognitive function? a scoping review. G. IOLASCON et al.
23. Ruiz-Ramos M, Vargas LA, Fortoul Van der Goes TI, Cervantes-Sandoval A, Mendoza-Nunez VM. Supplementation of ascorbic acid and alpha-tocopherol is useful to preventing bone loss linked to oxidative stress in elderly. J Nutr Health Aging 2010;14(6):467-72.
24. Knapen MH, Drummen NE, Smit E, Vermeer C, Theuvsen E. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int 2013;24(9):2499-507. doi: 10.1007/s00198-013-2325-6.

Anemia in pregnancy how to manage it without discomforts

CLASSIFICATION

Food supplement based on lactoferrin, derived from cow's milk, for the prevention and treatment of mild anemia in pregnancy.

NUTRITIONAL INFORMATION

	2 capsules
Lyophilized Lactoferrin	200 mg

CHARACTERISTICS

Lattoglobina is a lyophilized lactoferrin product from cow's milk, indicated in the treatment of hypoferremia and iron-deficiency anemia in pregnancy. Lactoferrin is a glycoprotein of the transferrin family, with a high iron-binding capacity. Studies of the 3D structure of lactoferrin showed the presence of two similar lobes, each has a site capable of reversibly binding a ferric ion (Fe^{3+}). Lactoferrin affinity for iron is 300 times higher than iron to transferrin. Numerous supporting studies demonstrated the high efficacy of Lattoglobina and the absence of the side effects typical of iron therapy.

INDICATIONS

Prevention ($\text{Hb} \geq 11 \text{ g / dL}$) and treatment of hypoferremia and mild sideropenic anemia ($10.9 \leq \text{Hb} \leq 10.0$) during pregnancy and lactation.

Efficacy and safety documented during pregnancy

- High compliance:
- Absence of gastrointestinal disorders
- Lactoferrin approved by the FDA as GRAS (Generally recognized as safe).

HOW TO USE

1 capsule twice a day (equivalent to 200mg of Lactoferrin) preferably on an empty stomach. Cycles for about 3 months are recommended.

AVAILABLE PACKAGES

30 capsules



Evidence-based literature:

- Variation of serum ferritin (+ 185%) in pregnant women affected by hypoferremia and iron deficiency anemia, treated with ferrous sulfate or Lactoglobina⁽⁵⁾;
- Variation of serum iron (+236%) in pregnant women with hypoferremia and iron deficiency anemia, treated with ferrous sulfate or Lactoglobina⁽⁵⁾;
- Variation in the number of red blood cells (+ 600%) in pregnant women suffering from hypoferremia and iron deficiency anemia, treated with ferrous sulfate or Lactoglobina⁽⁵⁾;
- Variation of Hb (+ 43%) in pregnant women affected by hypoferremia and iron deficiency anemia, treated with ferrous sulfate or Lactoglobina⁽⁵⁾;
- Variation in the value of hemoglobin (+ 117%) in pregnant women with hypoferremia and iron deficiency anemia, treated with ferrous sulfate or Lactoglobina⁽⁶⁾;
- Variation in the value of serum ferritin (+ 333%) in pregnant women affected by hypoferremia and iron deficiency anemia, treated with ferrous sulfate or Lactoglobina⁽⁶⁾;

Lattoglobina®

- Increased ferritin (+ 97%) in pregnant women suffering from iron deficiency anemia, treated with Lactogloblin and folic acid;
- Increased hemoglobin (+ 39%) in pregnant women suffering from iron deficiency anemia, treated with Lactogloblin and folic acid⁽⁷⁾;
- Lactogloblin + folic acid + ferrous sulfate: significant increase in (+ 30%) GR, (+ 22%) Hb, (+ 112%) ferritin, after 60 days of treatment.

Bibliografia

1. James M. Jay, A. Tedesco, P.M. Falcone, E. Gala, Martin J. Loessner, F. Licciardello, David A. Golden. Microbiologia degli alimenti. Springer p. 341.
2. Generally recognized as safe (GRAS) determination for cow's milk-derived lactoferrin as a component of cow's milk products and chewing gum. http://www.accessdata.fda.gov/scripts/fcn/gras_notices/GRN000464.pdf
3. Manzoni et al.: Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. 2009 Oct 7;302(13):1421-8. doi: 10.1001/jama.2009.1403.
4. Artym J, Zimecki M. The role of lactoferrin in the proper development of newborns. Postepy Hig Med Dosw. 2005;59:421-32. Review. Polish.
5. Paesano R. et Al. Ipoferremia e anemia da carenza di ferro in gravidanza. Evidenze cliniche della maggiore efficacia della lattoferrina, somministrata per os, rispetto al solfato ferroso. Il Ginecologo. Rivista di Ostetricia e Ginecologia 3 (suppl. al n. 1):1-6, 2008.
6. Paesano R. et Al. Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem. Cell. Biol. 84: 377-380, 2006.
7. Costantino D, Guaraldi C. Lattoferrina e anemia in gravidanza. Rivista Italiana Di Medicina Perinatale 2005, Settembre, vol. 7, n.3, 15-20.
8. Valenti et al, 2008 Valenti P, Pacifici E, Pietropaoli M et al. La lattoferrina per os, un'importante alternativa priva di effetti indesiderati, nella prevenzione e trattamento dell'ipoferremia ed anemia da carenza di ferro in gravidanza. Riv It Ost Gin 2008.
9. D., Guaraldi C. Anemia sideropenica in gravidanza: Lattoferrina vs ferro in varie formulazioni e idrolizzato di cartilagine di pesce marino. Il Ginecologo, Rivista di Ostetricia e Ginecologia Vol 4, Suppl. al No. 1 Marzo 2009.
10. Hiraku Onishi Lactoferrin delivery systems: approaches for its more effective use.
11. Suzuki Y.A., Lopez V., Lönnnerdal B. Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005; 62(22): 2560-75.
12. Ashida K., Sasaki H., Suzuki Y.A. et al. Cellular internalization of lactoferrin in intestinal epithelial cells. Biometals. 2004; 17(3): 311-5.
13. Vicariotto F. Lattoferrina: l'alternativa alla terapia marziale. Edit-Symposia Ginecologia & Ostetricia 2008/1.
14. World Health Organization (WHO). The prevalence of Anaemia in women: a tabulation of available information. Geneva, Switzerland: WHO; 1992. WHO/MCH/MSM/92.2.
15. Feirbanks V.F., Beutler E. Iron deficiency. In: Beutler E., Lichtman M.A., Coller B.S., Kipps T.J., eds. Williams Hematology. New York: McGraw-Hill; 2001. p. 447-70.
16. Bothwell T.H. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr. 2000; 72(suppl): 257-64.
17. Harris E.D. New insights into placental iron transport. Nutr Rev. 1992; 50(11): 329-31.
18. Cheng Y., Zak O., Aisen P. et al. Structure of the human transferrin receptor-transferrin complex. Cell. 2004; 116: 565-76.
19. Allen L.H. Anemia and iron deficiency: effects on pregnancy outcome. Am J Clin Nutr. 2000; 71(Suppl): 1280-4.
20. School T.O. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr. 2005; 81: 1218-2.
21. Leidi L. 2007, Lattoferrina: un nuovo approccio terapeutico per il trattamento dell'anemia sideropenica. Integratori terapeutici e fitoterapici nell'età riproduttiva, dello sviluppo ed avanzata. Ed 2007.

Lattoglobina complex®

CLASSIFICATION

A new nutritional approach in pregnancy.

Lactoglobulin complex is a food supplement based on lactoferrin, folic acid, Vitamin D, Vitamins B6, B1, B2, D and Vitamin C and with Zinc, Copper and Selenium.

NUTRITION FACTS

Medium contents	For a capsule	VNR
Lactoferrin	100 mg	-
Folic acid	400 µg	200 %
Vitamin D	5 µg	100%
Vitamin B1	0.55 mg	50%
Vitamin B2	0.7 mg	50%
Vitamin B6	0.7 mg	50%
Vitamin C	70 mg	87.5%
Copper	0.5 mg	50%
Zinc	5 mg	50%
Selenium	27.5 µg	50%

*VNR= Daily Reference Nutrition Value (Adult) (Reg. EU n.1169/2011)

INGREDIENTS

Lactoferrin; Hydroxypropylmethylcellulose (HPMC= vegetable capsule); Vitamin C (L-ascorbic acid); Cornstarch; Microcrystalline cellulose; Zinc (zinc citrate); Copper (copper gluconate); Anti-caking agent: magnesium salts of fatty acids; Vitamin D (cholecalciferol); Vitamin B6 (pyridoxine hydrochloride); Vitamin B2 (riboflavin); Vitamin B1 (thiamine hydrochloride); Folate (pteroyl-monoglutamic acid); Dye: titanium dioxide; Selenium (Selenium methionine).

CHARACTERISTICS

Lactoglobulin complex is a food supplement based on lactoferrin, folic acid, Vitamin D, Vitamins B6, B1, B2, D and Vitamin C and with Zinc, Copper and Selenium.

Folate contributes to the growth of maternal tissues during pregnancy; to the normal synthesis of amino acids; to normal hematopoiesis. Vitamin D contributes to normal levels of calcium in the blood and to the normal function of the immune system. Vitamins B6, B1 and B2 are necessary to support healthy bones. Vitamin C contributes to the normal functioning of the immune system, improves the absorption of iron. Zinc contributes to a healthy cardiovascular system. Copper contributes to the maintenance of normal connective tissues. Selenium contributes to normal thyroid and immune system functioning.

HOW TO USE

1 capsule a day, away from meals.

AVAILABLE PACKAGES

30 capsules.



MEDICAL DEVICES



Triacid ovules®

CLASSIFICATION

Medical device for intra-vaginal use

COMPOSITION

One ovule contains: Boric Acid, Hyaluronic Acid, Polycarbophyl, Lactic Acid, Tocopheryl Acetate, Vitamin A, 18-beta-glycyrrhethinic Acid, Tea Tree Oil, Semisynthetic Triglycerides, Phosphatidylcholine.

CHARACTERISTICS

TRIACID is a medical device that helps maintain the natural defenses of the vagina and enhances the recovery the normal vaginal flora; containing hyaluronic acid, boric acid and lactic acid it helps delete the symptoms due to unbalanced vaginal hydration and/or vaginal pH.

INDICATIONS

It is useful in the prevention and treatment of vaginal dryness also in mycotic character. It helps reducing irritations, burning and itching.

TRIACID IS USEFUL

- in the prevention and treatment of vaginal affections, because its formulation includes Lactic Acid.
- in mycotic character, because its formulation includes: Lactic acid; Boric Acid.
- Hyaluronic Acid (HA) and glycerin are very well-known substances able to improve skin hydration.
- Vitamin A, may decrease the risk of severe Bacterial Vaginosis (BV), a condition of altered vaginal flora.
- Vitamin E is able to stabilize the water-lipid interaction of the mucous secretions and, inserting among the phospholipids of cell membranes, increase the stability of the membranes themselves.
- Tea tree oil has antimicrobial activity, designed to neutralize bacteria, fungi and even viruses..

AVAILABLE PACKAGES

10 vaginal ovules of 2 g/ovule.



DRUGS



NAPREBEN[®] 10% gel

CLASSIFICATION

Napreben gel contains a new naproxen salt: naproxen betainate sodium with high efficacy for acute and chronic algesia of musculoskeletal and ligamentous apparatus.

NUTRITIONAL INFORMATION

A 50 g tube formulation contains:

Active substance: Naproxen betainate sodium 5 g

Excipients: hydroxyethyl cellulose, methyl p-hydroxybenzoate, sodium dehydroacetate, distilled water.

CHARACTERISTICS

Napreben gel has an elementary and balanced formulation without alcohol and fragrances. Due to its specific composition, it has a high topical tolerance, reducing the risk of allergies and topical inflammation.

INDICATIONS

Myalgia, back pain, stiff neck; fibromyositis, bursitis, tendonitis, tenosynovitis, periarthritides, bruising; muscle strains, sprains, bruising, edema and infiltrates traumatic. In addition, Napreben gel is indicated as adjuvant for orthopedic therapy and rehabilitation.

POSODOLOGY

3 applications per day.

AVAILABLE PACKAGES

Napreben 10% gel 50 g



Study carried out in patients by the Estense Hospital in Modena, Italy

Prof. Renato Lucchi et al. Evaluation of therapy with Naproxen betaine sodium (Napreben) in patients with painful symptoms and functional impairment affecting the osteoarticular system.

- Monitoring at T0, T5 (day 5), and T11 (the day after the last administration of the product), with three application daily, the pain regression index (comparing the pain levels in the first mornings of the treatment and the last evening) was significantly bigger ($p < 0.01$) in the treatment with naproxen betainate sodium versus ibuprofen.
- On the 5th day, the painful symptoms related to passive movement and the intra-articular functional capacity showed improvement as early as the first day of administration.

Some more evidence-based literature:

- Fast action and high absorption: a slower absorption occurs with the use of naproxen sodium. Plasma concentration of naproxen betainate, highly soluble, 20 minutes after oral administration of Napreben, is significantly higher ($p < 0.0001$) than that resulting from oral administration of naproxen sodium.³
- High tolerability: following a preclinical study, naproxen betainate showed a low ulcerogenic activity after single and repeated administration.

NAPREBEN[®] 10% gel

Bibliography

1. Prof. Giorgio Poggi et al., Valutazione del Pain Relief ottenuto con la somministrazione topica di un nuovo derivato salino del Naproxene (Napreben) [evaluation of pain relief after topical administration of a new Naproxen salt form (Napreben)], fondazione clinica del lavoro - Istituto Ricovero e Cura a Carattere Scientifico Centro medico di Riabilitazione di Montescano, 1988.
2. Prof. Renato Lucchi et al. Evaluation of therapy with Naproxen betaine sodium (Napreben) in patients with painful symptoms and functional impairment affecting the osteoarticular system. Estense Hospital, Modena, 1987.
3. Prof. Maggi G. et al., Bioavailability investigation of naproxene betaine sodium salt (Napreben capsule 550 mg) against naproxene sodium salt (Synflex tablets 275 mg) in healthy volunteers, 1987.





www.aqma.it
info@aqma.it
Milano
Via Vincenzo Monti, 16
Tel. + 39 081 552 43 00